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Abstract 
Purpose: The purpose of this capstone project is to explain from a market perspective the 
reasons for drug shortages that anesthesia, as well as the overall medical community, are 
experiencing. This capstone project will increase the anesthesia profession's awareness of root 
causes of sterile injectable drug shortages. The project will provide the anesthesia community 
with an understanding of the breadth of the problem, the underlying economical motivations, and 
the various stakeholders' positions. 
Methods: Stakeholder analysis and pharmaceutical market evaluation were conducted by 
examination of current literature, white papers, subject-matter expert interviews, and government 
agency reports. Information collected is analyzed using economic market theories, carefully 
aggregated/categorized to develop a clear understanding of the current drug shortage crisis. 
Results: Key stakeholders, drug manufacturers, government agencies' regulations, group 
purchasing organizations (GPOs), and raw material suppliers are cited most often as a "Primary 
Effects" or a root cause of the sterile injectable drug shortages. The "Secondary Effects" 
category does not cause drug shortages; they exacerbate existing shortages. Drug manufactures, 
healthcare facilities, and wholesaler distributors were implicated in the "Secondary Effects" 
category. Eight of the nine stakeholders were linked to "Safety Issues" related to drug shortages. 
Five stakeholders contributed to a category that addressed "Consequences of Drug Shortages". 
While these consequences do not playa role in the root cause of drug shortages, they have a 
significant effect on stakeholders and the market environment. 
Conclusions: The sterile generic pharmaceutical market shortages are unlikely to equilibrate on 
their own. Complicated relationships among stakeholders and non-market issues impede the 
generic market from self-correcting. Therefore, some form of intervention is needed to resolve 
the shortages. Options will need to be carefully analyzed to avoid further market disruptions, as 
previous well-intended interventions to correct the market had unintended consequences. 
Data Sources: Google Search, Google Scholar, PubMed, Government Archives, ProQuest 
Business, and Government Web Sites 
Keywords: Drug shortages, anesthetic drug shortages, drug shortage causation, market failure, 
drug shortage explanations 
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Introduction and Background 
The FDA defines drug shortage as "a situation in which the total supply of all versions of 
an FDA-regulated drug is inadequate to meet the current or projected demand at the patient 
level.,,1 Over the past decade, the United States (U.S) has experienced a dramatic increase in the 
number of prescription drugs that have become inaccessible to the public. The crisis reached its 
peak in 2011 with 250 prescription drugs (hereafter drugs) on the shortage list; this is over four 
times the amount that was recorded in 2005 when there were 61 documented shortages.2 Due to 
the escalating nature of the crisis and the detrimental impact on society as a whole, President 
Obama issued an executive order directing the Food and Drug Administration (FDA) to expand 
reporting of the potential shortages of certain drugs. Additionally, the executive order requires 
the FDA to expand its efforts for an expedited review of new manufacturing sites, new drug 
suppliers, and manufacturing changes to help prevent future drug shortages. 3 
The drug shortage has negatively impacted the healthcare community. From January 1, 
2010 to August 26, 2011 the FDA tracked drug shortages. Of the 127 drugs tracked, 118 of 
those shortages, 93 percent, which were categorized as "medically-necessary". 1 ,4,5 A medically 
necessary drug product is a drug that is used to treat or prevent a serious disease or medical 
condition for which there is no alternative drug available in adequate supply, and which is 
determined by the medical staff to be an adequate substitute.6 Currently, shortages are heavily 
concentrated in the area of sterile injectables (73%) cancer drugs, anesthetic used for surgery, 
emergency medicine, and electrolytes. 7-10 
The U. S. economy is based on a market system. Supply and demand is the driving force 
behind a pure market economy and government involvement (regulation) is generally minimal to 
nonexistent. Occasionally, government plays a part in influencing the market process.7 
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Generally, Prices in the market change to keep the quantity supplied and quantity demanded 
equal overtime. Prolonged shortages and surpluses are uncommon in most markets. In 
functioning and unrestricted markets, basic economic theory states that prices will fluctuate 
depending on supply and demand. In this capstone study, "market" here after refers to the 
pharmaceutical market. 
5 
The basic premise of supply and demand market forces is that if there is a shortage the 
natural tendency of market prices is to rise. The opposite occurs with a surplus, as market prices 
are expected to fall. The interaction of market supply and demand thus determines the 
competitive price at which there would be no long-term shortages or surpluses of goods. This is 
referred to as price equilibrium and market forces are in balance. 7 Once equilibrium is reached, 
there is no tendency for prices to rise or to fall. The equilibrium price equates quantity 
demanded with quantity supplied. 7 
The drug shortage is generally characterized as a supply-side issue.8,9 There is not a 
sufficient supply of particular types (for example, sterile injectable generics) of drugs available 
to satisfy the demand for those drugs. The law of supply states that there is a direct positive 
relationship between the price of goods and the amount of those goods manufactures are willing 
to produce. t 0 The price and the quantity supplied will move in the same direction. If the price 
increases, then it can be expected that quantity supplied will increase. In contrast, as prices fall, 
the quantities manufactures are willing to produce will decrease and subsequently the supply will 
be less. tO If the price is too low, the quantity demanded by the consumers will exceed the 
quantity supplied. to In other words, this would cause a shortage of those goods. 
Unlike other goods, pharmaceutical drug sales are affected by unique non-market factors 
such as government regulations, insurance coverage, and patent protection. These external 
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factors influence the supply and demand in the pharmaceutical market and they cause atypical 
results when compared to other markets. 
6 
Price elasticity is another factor that affects supply and demand. Price elasticity of 
demand indicates how responsive consumers are to changes in the price of the product. As a 
rule, the prices of non-essential goods are usually elastic and demand fluctuates significantly in 
response to price changes. The demand for most necessities, such as medications, is relatively 
inelastic and demand does not change significantly with price variations. The most important 
determinant of the price elasticity of demand is the availability of substitutes. When good 
substitutes (i.e. competitive products) are available for a particular drug a price increase will 
cause consumers to switch to other substitutes and demand would be more elastic. 10 This market 
reaction is especially true for pharmaceuticals. 
Healthcare facilities have been affected by the drug shortages on multiple fronts. The 
financial impact, compounded by the detrimental health effects to patients, has the healthcare 
system reeling. The drug shortages have spiraled out of control and have had significant 
negative effects on healthcare facilities and patients. The drug shortage impacts on patients are 
numerous and not likely to change in the near future. When first-line drugs are in short supply, 
physicians are often confronted with limited treatment options since many drugs do not have 
suitable substitutes. For example, Cytarabine is the only known drug used to treat acute 
myelogenous leukemia (AML).11 AML is a fast spreading cancer that can terminate a patient's 
life within three months if not treated. Without Cytarabine, the survival rate of AML is zero. 11 
Problems also occur with the increased use of alternative drugs as replacement for the original, 
which creates an increase in demand for the substitute. Subsequently, increases in demand result 
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The drug shortages are not resolving on their own and there is no indication that the 
pharmaceutical market will naturally equilibrate in the near future. The major shortages are 
concentrated on sterile generic injectable medications that have been around for decades and are 
used every day in the medical community. The questions to be answered are: Why are there so 
many drug shortages? How do drug shortages occur and why has the sterile generic 
pharmaceutical market not adjusted? When can the medical community expect some relief from 
the persistent drug shortages? 
Aims and Objectives 
Aims: The aim of this paper is to propose a comprehensive explanation of the drug 
shortages, safety factors and associated consequences of the drug shortages. This information 
will be compiled and evaluated formulating a clearer understanding of the drug shortages. Why 
do drug shortages occur? How do drug shortages occur? What are the repercussions of drug 
shortages? 
Objectives: Stakeholders' interest and position are presented and compared to well-
established economic theories in order to develop a comprehensive overview of potential causes 
and consequences of the drug shortages. Market factors that contribute or play an essential role 
in the drug shortages are investigated and explained. 
Stakeholder Analysis and Literature Review 
This paper explores the underlining reasons that have led to a nationwide drug shortage 
and focuses on generic sterile injectable drugs since they represent the largest share of current 
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shortages. It also explores the reasons why the U. S. pharmaceutical market has not self-
adjusted. Understanding the key stakeholders' interests and positions is essential for analysis of 
the problem. Stakeholders' positions are examined with respect to their association to the 
current drug shortages. 
Stakeholder analysis for this paper is the process of systematically gathering and 
analyzing qualitative information to determine interests and positions of key stakeholders in 



















The pharmaceutical industry is comprised three main players: brand pharmaceuticals 
("Big Pharma"), branded generics and generics. Brand pharmaceutical companies manufacture 
drugs that have trade names and are protected by patents. Patents allow companies to have 
exclusive rights for 20 years from the date of filing. However, it usually takes an estimated 7 - 9 
years, to get FDA approval, before a drug reaches the market, thus decreasing pharmaceutical 
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companies' exclusive rights to market a specific drug. 12 After the patent expires, generic drug 
companies can petition the FDA to make and market a bioequivalent version of the previously 
protected medication. The generic drug company requests an "abbreviated new drug 
application" (ANDA). In this application, generic manufacturer must show that the new drug is 
the bioequivalent of the branded medication that is no longer patent-protected. From 2010-2015, 
brand pharmaceutical companies faced the largest patent expiration surge in history.13 This 
phenomenon is dubbed the "patent cliff'. 13 Once a patent expires, a drug's price can drop up to 
90%.13 A branded generic drug is the bioequivalent to the original but is now marketed by the 
original company's brand name or another company's brand name. The branded generic is 
priced higher than the unbranded generic but less than the previously patent protected brand 
drug. 
In past years, the pharmaceutical and vaccine markets have had sporadic shortages of 
individual drugs and intermittent shortages of several drugs belonging to a specific class. I4 
Brand pharmaceuticals (patent protected drugs) account for 11 % of drug shortages, with generic 
drugs (no patent or exclusivity) representing 83% of2011 shortages. IS The recent drug 
shortages, however, have been sustained and concentrated in the generic sterile injectable 
market. 14-17 According to the FDA in 2013, 80% of the drug shortages were confined to generic 
sterile injectable drugs. 1 8-20 In 2011, the IMS Institute for Healthcare Informatics analysis 
uncovered shortages of drugs: prior to the 1970s - 30 drugs; in the1980s - 58 drugs; in the 1990s 
- 37 drugs; in the 2000s - 38 drugs and in 2010 - 4 drugs: s The shortages tend to be older, less 
expensive generic drugs with 75% being introduced before 2000. Drug products that remain on 
the shortage list are concentrated in five areas: oncology, cardiovascular, central nervous system, 
anti-infectives, and pain. IS Healthcare specialties of oncology, anesthesia, and emergency 
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medicine have been hit the hardest. 14,21,22 Intravenous electrolyte solution (.9 normal saline) 
shortages have affected all specialties across the board. Researchers at the IMS found that half 
of the generic injectable drugs in the United States were reported on the shortage list. 15,16,21 , 
Quality and manufacturing problems have been linked to the majority (64%) of the 
shortages of sterile injectable drugs. 18,23 A FDA "Drug Information Specialist" stated in an email 
correspondence: 
All sterile generic injectable drugs are not manufactured in the United States, some of 
these are manufactured overseas. I do not have specific percentages that are 
manufactured outside of the United States. Six manufacturers make up most of the 
market. These firms may do contract manufacturing as well as manufacture their own 
products24 
Not all production disruptions result in shortages; however, all shortages are preceded by 
disruptions in manufacturing.25 The chart below provides reasons for sterile injectable 
shortages: 
Reasons for Drug Shortages: 2013 
37% 
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"SUei 
• l>Isconhnuallon 
• Raw Malcna" (APJ) 
• Jncn:JUCd Dnnand 
• Lou ofMf~ Site 
source: FDA Figure 2. Reasons for Drug Shortages: 2013 
The generic drugs in the U. S. have very low profit margins.2o,26 These drug shortages 
are likely related to decreased incentives for the manufacturers to produce off-patent 
medications. 8 It has been suggested that the primary cause of generic injectable drug shortages is 
the lack of financial incentives for the industry to invest in updating manufacturing facilities and 
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to provide quality control systems.25 Since profit margins are so low, manufacturers attempt to 
produce drugs as inexpensively as possible by using older and less efficient facilities that have 
antiquated equipment. 27 It has been proposed that shortages in the sterile generic industry are a 
consequence of extensive expansion in scope and volume of products without a corresponding 
expansion in manufacturing capacity.28,21 Without expanding capacity, new more profitable 
opportunities force difficult business decisions resulting in a discontinuation or decreased 
production of the older and less profitable drugS.21 
Biologic medications being replaced by biosimilars are examples of new opportunities. 
Biologic drugs comprise 22% of brand pharmaceutical drug sales and it is predicted to grow to 
32% by 2023.29 Biologics (large molecule products) are complex medications made of or 
extracted from living cells, blood components, and tissue. These medications treat life-
threatening illness such as multiple sclerosis, anemia, hemophilia, cancer, diabetes, HIV, and 
rheumatoid arthritis. The FDA's definition of biologics is: 
Biologics are isolated from a variety of natural sources - human, animal, or 
microorganism - and may be produced by biotechnology methods and other cutting-edge 
technologies. Gene-based and cellular biologics, for example, often are at the forefront of 
biomedical research, and may be used to treat a variety of medical conditions for which 
no other treatments are available.3o 
In the U.S., biologics had little competition until the Biologics Price Competition and 
Innovation Act (BPCIA) was included in the Affordable Care Act (ACA).31 An interchangeable 
biological product is considered a biosimilar. Biosimilars are a relative new opportunity within 
the U.S. drug market. By the year 2020, it is projected that biologics will lose $100 billion in 
sales as patent protection expires and new biosimilars enter the market. 32 
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The FDA defines biosimi1ars as: 
A biosimi1ar product is a biological product that is approved based on a showing that it is 
highly similar to an FDA-approved biological product, known as a reference product, and 
has no clinically meaningful differences in terms of safety and effectiveness from the 
reference product. Only minor differences in clinically inactive components are allowable 
in biosimi1ar products. 33 
The global biosimi1ar market is projected to be $20 billion by 2020.34 
European countries have been using biosimilars since October 30, 2006. Biosimi1ars are not 
generics. Biosimilars must complete an extensive clinical comparability trial and are more costly 
to manufacture than other drugs.35 For example, Zarxio is the biosimi1ar to Neupogen, which 
ilnproves white blood counts to fight infections.36 On September 3, 2015, Zarxio was the first 
biosimi1ar to appear on the U.S. market.36 
The "patent cliff' increases the number of drugs available to the generic market. 13,37 Low 
profit margins of the older generic drugs have caused many drug companies to shift resources to 
higher profitable brand generics or new drugs that have recently come off patent. Another 
business strategy has been the development of "super generics". Super generics are generic 
drugs that are improved by manufacturers. These improvements may be due to the method of 
delivery, manufacturing processes, and/or reformulation technology. The super generic drugs 
enjoy a significant price premium.26 
Many manufacturers produce low profit generic drugs in order to win group-purchasing 
contracts.38 It is not a profitable endeavor; however, it allows the manufacturer to get their "foot 
in the door" in hopes of increasing the sales of pharmaceuticals that are more profitable. 
Manufacturers may view some generics as "loss leaders" and the cost of doing business.2o,38 A 
loss leader is a product that is sold at a loss to attract business.39 
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The trend of consolidation in the drug manufacturing industry has significantly decreased 
the number of players in the field. 1,17,19,20 The industry is concentrated with only six to seven 
main players making up 85-90% of the market. 19,40 According to the FDA, the top three 
manufacturers accounted for 71 percent of generic injectable drug sales in 2010?1,41 In most 
cases, three or fewer manufactures supply a specific generic injectable drug. 14,15,19,20 The IMS 
Institute for Healthcare Informatics reported that in 2011, 168 products on the shortage list had 
no suppliers, 56 had one supplier and 23 had two suppliers. 15 This is partly due to company 
mergers which affect production capabilities if decisions are made to discontinue products and/or 
narrow product lines. The decrease in the number of manufacturers makes the market 
susceptible to drug shortages if there are any disruptions in production by the remaining 
manufacturers. 
The generic pharmaceutical industry continues to consolidate with mergers and 
acquisitions. In February 2015, Pfizer announced its intention to acquire Hospira. The largest 
maker of sterile injectables in the world Hospira has two of the four applications for biosimilars 
pending the FDA's approval.42 In September 2015, the deal between Pfizer and Hospira was 
completed. The acquisition of Hospira placed Pfizer in a dominant position in biosimilars. Pfizer 
stated: "We've created value for our shareholders ... expected earnings per share (EPS) to 
grow ... by strengthening our Global Established Pharmaceutical (GEP) business and positioning 
it for future growth.,,43 In November 2016, Pfizer announced that it would buy Dublin-based 
Allergan with the intention of moving Pfizer's headquarters to Ireland for the purpose of slashing 
its U.S. tax bill.44 The merger, barring any divestments, created the world's largest drug maker 
by annual sales of approximately $60 billion.44,45 
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Market consolidation may cause some drugs to be produced by only one manufacture. 
This has caused a sudden increase in market activity that has prices of single-supplier drugs 
skyrocketing. Tetracycline, a drug that entered the market in 1967, has increased in price from 
November 2013 - November 2014 from $.05 (.048493) per tablet to $ 8.59 per tablet (17,714% 
price increase).46,47 Digoxin, a drug that has been used for decades to treat some heart 
conditions, experienced a price increase in one month from $131 per bottle to $989 per bottle 
(655% increase).48 Another, perfect example of this is Duraprim, a 62 year-old drug that is used 
to treat life threatening parasitic infections (toxoplasmosis and malaria).49 Turing 
Pharmaceuticals, a new start-up company, acquired the drug from Impax Laboratories.5o The 
CEO, Martin Shkreli a former hedge fund manager, leveraged monopoly power to raise the price 
overnight from $13.50 to $750 per tablet.49,50 
Lack of redundant capacity has also been cited in the literature as a problem.4o This is 
defined as the availability of another line or facility to produce the same product if disruption of 
the primary production source should be disabled. 51 For example, some manufacturers operate 
one to ten facilities, which manufacture several product lines.28 A specific drug can be produced 
on one or two of these lines (separate batches), which may continuously produce for hours to 
weeks?5 Many facilities operate 24 hours / 7 days per week.25,21 There are operational costs 
when switching from one drug to another. 14 Most facilities have been operating since the 1960s 
with minimal upgrades. From an economic point of view, low profit margins make upgrading 
aging facilities unattractive.25 In addition, the manufacturing process for sterile injectable 
generic drugs is very complex and costly resulting in low profit margins. 1,8,21,40 
The regulatory compliance in the generic pharmaceutical industry has come under 
scrutiny. Compliance violations, both civil and criminal, have plagued the industry for years. 
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Current Good Manufacturing Practices (CGMP) are regulations enforced by the U.S. Food and 
Drug Administration (FDA).52 The Consumer Protection Branch (CPB) is part of the 
Department of Justice (DOJ). The CPB enforces civil litigation and criminal prosecutions to 
protect the public health sector and consumers.53 The FDA and CPB work closely together with 
a common goal of protecting the American people. Below are some examples of violations that 
were discovered by the CPB:53 Ben Venue 2011 in a civil suit was convicted of 48 compliance 
violations that resulted in 40 recalls since 2002.53 SB Pharmco, a subsidiary of GlaxoSmithKline 
(GSK), in 2010 pled guilty to felony charges related to the manufacture and distribution of 
adulterated drugs; a criminal offense that carried $750 million in fines.53 In 2006, a criminal 
case against Ranbaxy, in which the company pled guilty to four felony counts of making false 
statements to the FDA, was fined $150 million. 53 Other companies that were indicted in criminal 
cases that incurred fines were Johnson & Johnson ($1.5 - 2 billion), Merck ($950 million), Eli 
Lilly ($1.4 billion), Abbott ($1.5 billion), Pfizer ($2.3 billion), and Purdue Pharma ($663 
million )54,55 
The FDA has been as a contributing factor to the drug shortages by holding the drug 
manufacturing industry accountable for regulatory and quality compliance. This has caused 
delays, interruptions, and prolonged facility closures.8 Quality problems in manufacturing are 
accountable for a majority of the sterile generic drug shortages. 14 Regulatory and quality 
compliance issues increase the cost of production, forcing manufacturers to make difficult 
business decisions.8 In 2011, one key manufacturer, Ben Venue Laboratories, made a business 
decision not to refurbish its manufacturing facility.56 Deemed unsustainable for the long term, 
Ben Venue's management decision was based on the level of financial investment required to 
guarantee product quality.56 
WHY SO MANY DRUG SHORTAGES 16 
Changes in inventory practices can alter the availability of the drug supply. 
Manufacturers often decrease inventory by following "just-in-time" (JIT) inventory practices, 
which are meant to optimize cash flow and decrease the carrying cost of inventory. 1,19,21 The 
perfect JIT system would have zero inventories after meeting all of a company's demand. With 
JIT, there is a fine line between having too much inventory and not having enough. The 
"Goldilocks Principle" epitomizes the inventory condition; it needs to be "Just Right". With JIT 
it is difficult to adjust production volumes on short notice. Unanticipated changes in demand 
may occur without much advance warning. This leaves the industry vulnerable to interruptions 
in the flow of raw materials or other supply chain disruptions. 1,19 
In addition, disruptions in the supply of raw materials have been frequently cited as one 
factor responsible for causing delays in the drug manufacturing process.8 In 2011, raw material 
availability was not a major cause of drug shortages with a reported incidence of only 3%.28,57 
However, in 2013, the FDA (Figure 2) noted that the supply of raw material was implicated in 
drug shortages 27% of the time.58 Sole-source suppliers are particularly problematic; there may 
be several producers of specific drugs but only one supplier of the raw materials.8,59 An 
interruption in raw material flow affects all manufacturers that require that essential component. 
Approximately 800/0 of the drug manufactures raw materials are imported from foreign 
suppliers.8,6o This makes U.S. drug manufacturers dependent on the global supply chain and 
susceptible to economic changes in other countries.61 
Group Purchasing Organizations 
Most hospitals do not purchase drugs directly from manufacturers; they use Group 
Purchasing Organizations (GPO). GPOs collectively negotiate contracts with manufactures on 
behalf of their customers (hospitals). Most Hospital purchases (72%) are made through 
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GPOS14,62 Consequently, GPOs have a tremendous amount of negotiating power. 14 The first 
hospital group purchasing organization established was the Hospital Bureau of New York in 
1910. GPOs developed slowly and by 1962 there were ten.63 By 1974, the number of GPOs had 
increased to 40, propelled by Medicare and Medicaid reimbursement changes.64 In 1983, a 
revision to Medicare changed the payment structure from a "fee-for-service" (FFS) payment to a 
Prospective Payment System (PPS).64 PPS provides a fixed payment per patient with a given 
diagnosis. The increased focus on cost stimulated rapid growth for the GPOs and by 2007 there 
were hundreds of healthcare GPOs. It is estimated that today there are over 600 GPOS.64-67 
The Healthcare Supply Chain Association (HSCA) differentiates GPOs: 
They vary greatly in size, type of ownership and services they offer. Some GPOs are 
owned by hospitals, while others do not have a link to the facilities they serve. Some 
GPOs serve non-profit organizations, others serve proprietary facilities and some serve 
both. Some GPOs offer hospitals the ability to purchase nearly every conceivable 
product, while others focus on specific products. 64 
The Office of the Assistant Secretary for Planning and Evaluation (ASPE) report states: 
"The GPO market is relatively concentrated with five GPOs commanding 85-90% of the 
market".14,28,68 While another source states that there are seven large national GPOs in the 
United States.69 In 2014, the United States Government Accountability Office (GAO) 
acknowledged that a small number of GPOs dominate the healthcare market. 67 There are also 
local and regional GPOs. However, their purchase volumes are insignificant compared to 
national GPOS.69 Many of the smaller local and regional GPOs are actually members of one of 
the larger national "parent" GPOs.70 This explains the large disparity in the reported numbers for 
GPOs. 
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Most GPOs charge administrative fees, which are percentages based on the size of the 
contracts. The drug manufacturers are charged these administration fees. The "pay to play" 
payment structure would be considered illegal kickbacks by other industries. 
Medicare and Medicaid Patient Protection Act (MMPPA) of 1987 provides GPOs with "Safe 
Harbor Provision" protection from anti-kickback statutes. The MMPPA states: 
GPOs may be allowed to provide goods or services to a hospital or healthcare provider as 
long as both of the following two standards are met - (1) the GPO must have a written 
agreement with each hospital or healthcare provider, that provides for either of the 
following agreement: (a) The vendor from which the hospital or healthcare provider will 
purchase goods or services will pay a fee to the GPO of3% or less of the purchase price 
of the goods or services provided by that vendor, and (b) In the event the fee paid to the 
GPO is not fixed at 3% or less of the purchase price of the goods or service, the 
agreement specifies the exact percentage or amount of the fee. (2) The GPO must 
disclose in writing to the hospital or healthcare provider at least annually, the amount 
received from each vendor with respect to purchases made by or on behalf of the hospital 
or healthcare provider.64 
The GPOs negotiate the lowest possible prices with manufacturers. GPOs then sign long-term 
contracts with manufactures, locking in prices and restricting any price fluctuations in response 
to market conditions. "GPOs are a major, if not the primary, contributor to the market 
distortions in the healthcare industry in the United States" said S. Prakash Sethi, Ph. D. "Through 
exclusive contracting, which has given GPOs effective control of this industry, they have 
contributed to product shortages and disincentives for legitimate producers to manufacture and 
stock essential drugS.,,71 ,19 
Literature varies extensively regarding impact of GPOs on drug shortages. In order for 
GPOs to secure low prices, a GPO must exercise some measure of monopsony power, which 
raises competition concerns.72 An article by Blair and Piette has described GPOs as having 
monopsony power.72 Monopsony is defined as a "market in which there are 11lany sellers but 
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only a single buyer, who thus is able to control the price and availability of the goods offered".73 
When this occurs, one or a few, purchasers have so much power that they can command lower 
pnces. 
However, Lindsay writes in her paper regarding anti-trusts, that without a company 
controlling 35% of the market, monopsony is unlikely.74 Literature also depicts the GPO 
industry as 0Iigopolistic.68,75,76 An oligopoly is defined as "a market structure in which there are 
only a few firms, each of which is large relative to the total industry".7 Oligopolistic industries 
characteristically have three to four companies that control 50% or more of the market.68 Baye 
explains in his book on Economics and Business Strategy, that the number of companies 
required is not exact and an oligopoly typically can occur when there are between two and ten 
companies.7 The number of GPOs in the industry is reported to be greater than 600 but only 5-7 
firms control 85-90% of the market. Dominance by a few rather than the total number in the 
industry is the determining factor in an oligopoly.77 By definition, the GPO market would be 
considered oligopolistic. 
Key characteristics of firms in concentrated markets include interdependence, strategy 
dependent, and high barriers to entry.78 The Game Theory is used to model behavior in an 
oligopolistic environment.7 In an oligopoly, each player (company) knows that its profit depends 
on actions of the other players. Collusion is a key characteristic of oligopolies. 78 Players collude 
so they can enjoy monopoly benefits. In an oligopolistic market firms may attempt to collude 
instead of compete. 78 When a few firms dominate the market, they can profit by "agreeing" to 
certain behavior that benefits the colluding companies at the expense of consumers and/or 
suppliers. Collusion is illegal in the United States. However, forms of collusion that are not 
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obvious (tacit) are very difficult, if not impossible, to prove. Companies may use nonverbal 
"signaling" to convey information. 
Dr. Sethi in his book "Group Purchasing Organizations: An Undisclosed Scandal in the 
U.S. Healthcare Industry" states that today most GPOs are privately held for-profit 
organizations. He further describes how these big corporate giants seem to put the financial 
interest of their owners above their clients to whom they owe their fiduciary duty.68 Moreover, 
private ownership has permitted most GPOs' financial information to be withheld from the 
public. Sethi also remarked on how the "companies claim to save hundreds of millions of 
dollars", that he feels, has not been substantiated.68 
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Lawton Robert Bums, Ph.D., MBA, professor at the Wharton School and lead author of a 
paper prepared for the American Hospital Association (AHA) and the Association for Healthcare 
Resource and Materials Management (AHRMM) shares a different perspective. "Our study 
shows that not only do GPOs provide cost savings, but they help hospitals meet their need for 
physician preference items".79 
In recent years, GPOs have been the focus of lawsuits from small manufacturers and have 
come under fire for unfair competitive behavior, which has initiated investigations by Congress 
(GAO).75,79,80 The government investigation consisted of four Senate judiciary Committee 
Hearings on GPO contracting practices and a succession of GPO performance reviews. The 
Senate requested that the GAO conduct the performance audits.79 The critics of the GPO 
practices demanded the repeal of the safe harbor for the GPOS.79,81,75 
Premier, a national GPO's, relationship with American Pharmaceutical Partners (APP) 
came under scrutiny in an article written by the New York Times (NYT). American 
Pharmaceutical Partners had a national contract with Premier serving 1500 hospitals.68,82 In 
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APP's short history, it recalled 20 different drugs, and the FDA has warned the company three 
times to fix serious quality control problems.82 Premier had a financial interest in APP's success 
as a drug company.82 Premier received a percentage of the money that hospitals spent buying 
APP's drugs.68,82 WillimTI J. Nydam, received stock options ($1.2 million) as an American 
Pharmaceutical director during the time he was executive Vice President ofPren1ier.82 Premier, 
by promoting the pharmaceutical company as one of its "elite" suppliers, literally turned a non-
asset company into one that raised $144 million in its initial public offering. 82 
The NYT reported that Senator Kohl, chairman of the antitrust subcommittee, referred to 
the incident as "scandalous". 82 The NYT article was released March of 2002 and in April 2002 
the Senate held a hearing to review GPO practices. During the hearing Senator Kohl demanded 
that within 90 days GPOs produce a code of conduct. 83 In response to the GAO investigations, 
the Healthcare Supply Chain Association (HSCA) made a decision to implement a code of 
conduct in an attempt at self-regulation. Furthermore, Premier, one of the largest GPOs, adopted 
additional principles to regulate contracting practices.79 Critics to self-regulation argued that the 
code of conduct was voluntary, non-uniform, reversible, non-enforceable and did not carry any 
penalties for GPOs that were non-compliant. 79 The GAO reported the results of the audits that 
were performed in 2002 and 2003 and found that prices were not always lower when purchased 
by the GPO.75 GPO prices were often higher than when hospitals independently negotiated with 
venders.75,84 The latest GAO report (October 2014) looked at the funding structure of the GPOs. 
The GAO found that the literature and views of experts varied greatly. Consequently, the GAO 
investigation was inconclusive stating that there is very little empirical evidence available to 
either support or contradict claims one way or another.85 
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The GAO stated that revoking safe harbor could disrupt the healthcare supply chain in the 
short-term.85 However, GPOs and hospitals are likely to adapt to the new market environment in 
the long-term.85 It was decided that repealing the safe harbor provision would need further 
investigation and clearer understanding of the impact of the GPO funding structure and the 
implications to hospitals.85 
Healthcare Facilities 
The healthcare experts at the University of Pennsylvania-Wharton predict the trend of 
hospital consolidations will continue at a fast pace, particularly as health systems move more 
toward Accountable Care Organizations (ACO) in response to the Affordable Care Act (ACA).86 
It is well documented that the ACA has stimulated a wave of hospital consolidations as hospitals 
band together to gain power in an uncertain economic environment. 86-89 The ACOs tie 
reimbursement amounts to improvements in quality and reductions in the total cost of care. In 
order for hospitals to survive in a tough economic environment, there has been an increased 
number of mergers and acquisitions in attempt to gain market share, to take advantage of 
economies of scale, to improve leverage with managed care plans, to reduce administrative cost, 
to improve access to capital, and to limit duplication of clinical programs. 90 Data from the 
American Hospital Association (AHA) shows the number of hospitals in 1993 was 5,261, and by 
2013 the number decreased to 4,974.91 The biggest decrease was in the rural sector with the loss 
of278 hospitals compared to 9 in urban areas.91 The trend for independent hospitals is to be 
incorporated into healthcare systems that have an affiliation with academic medical centers. 87 
Similar to drug manufacturers, hospitals cut costs and control cash flow using 'just-in-
time" inventory practices. This inventory approach has exacerbated the drug shortages for 
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healthcare facilities because they do not have enough inventories to buffer against the impact of 
the unexpected interruptions in drug supplies. 8,21,57 
Furthermore, hospitals with good intentions may contribute to the drug shortages by 
stockpiling drugs that are or are rumored to be in short supply.92,93 In 2011, a survey from the 
American Hospital Association indicated that 85% of hospitals purchased excess inventory in 
response or anticipation to drug shortages. 21,94 Hoarding in anticipation of or during a shortage 
can exacerbate the shortage and can cause a supply and demand mismatch.59,92 Some hospitals, 
due to stockpiling or hoarding of drugs, may have an abundance, while other hospitals are unable 
to secure enough to fulfill daily requirements. Hospitals that stockpile can cause artificial 
shortages by draining the supply chain and can exceed manufacturers ability to meet the quantity 
demanded. 59 Additionally, holding excessive inventory increases hospital costS.92 With the 
overstocking of inventory, drugs may expire and hospitals may be forced to discard expired 
drugs and thereby increase waste. 
Unintended consequences may occur when hospitals are desperate to provide drugs that 
are no longer attainable through their customary supply chain process. In many instances, 
hospitals turn to compounding pharmacies.95-97 The FDA defines cOlnpounding as "a practice in 
which a licensed pharnlacist, a licensed physician, or, in the case of an outsourcing facility, a 
person under the supervision of a licensed pharmacist combines, mixes, or alters ingredients of a 
drug to create a medication tailored to the needs of an individual patient".98 The FDA states that 
compounding phannacies play an important role helping people that have special needs. These 
needs lnay be due to an allergy to an inactive ingredient or for a patient that nlay require a route 
that is not available, such as in liquid or suppository fonns. However, the FDA warns that, 
"consumers need to be aware that compounded medications are not FDA-approved; this means 
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that FDA has not verified their quality, safety, and/or effectiveness. ,,99 Since the drug shortage, a 
new troublesome trend has emerged as firms with pharmacy licenses are making and distributing 
drugs outside the traditional compounding boundaries.99 These operations appear to be acting 
similar to manufacturers formulating large amounts of injectable drugs that transcend state 
boundaries.95,99 In the U.S., it has been reported that there are 7,500 pharmacies that specialize 
in compounding. 95, I 00 
Multiple mishaps have been linked to the actions of compounding pharmacies in recent 
years. In 2012, an outbreak of fungal meningitis was linked to a compounding pharmacy in 
Massachusetts.99,101 As of December 2012, tainted steroids were traced to 76 healthcare facilities 
in 23 states. 102 The steroid contamination at least 39 individuals, and there were 620 cases of 
meningitis and other illnesses reported. 102 It is estimated that 13,534 patients were exposed to 
contaminated drugs through epidurals, spinals, peripheral joint injections, or other therapeutic 
treatments. 103, I 04 The drug shortage has led to a steady increase in the use of compounding 
pharmacies. \05 The FDA does not review formulations for compounding and has no control of 
the quality and consistency of the process. \06 
When drug shortages occur, doctors, pharmacies, and hospitals have to modify 
therapeutic strategies. When a shortage of a primary drug occurs and if a substitute drug exists, 
the sudden increased utilization (unexpected demand) of the substitute drug can cause a 
secondary shortage of that substitute drug.57,107 This leaves the medical community with limited 
or nonexistent treatment options. 
The drug shortages have been devastating to healthcare facilities. Unexpected shortages 
and the large economic impact due to unanticipated costs have many hospital systems struggling 
to provide adequate patient care. The unanticipated shortage leaves little time for adjustments or 
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alternative plans. Communication is poor and sometimes nonexistent. In many cases, 
alternatives could have been put in place with prior knowledge of the impending shortages. In 
addition, a study by clinicians at the University of Michigan Health System (UMHS) found that 
annual labor cost for managing drug shortages were estimated at $216 million. 1 08 In addition to 
the labor cost Premier Healthcare Alliance estimated that acquisition of alternative therapies and 
more expensive drug substitutes could increase hospital cost $200 million annually. 109 The 
increased economic burden placed on already strained hospital systems could be disastrous for 
patients. 
Healthcare Professionals 
A healthcare professional for the purpose of this paper is described as any person that 
prescribes, dispenses, procures, or administers drugs in a therapeutic setting. This definition 
includes physicians, pharmacists, nurses, and other professionals. Each healthcare professional 
provides essential aspects in the pharmaceutical therapeutic milieu. One purpose unites all 
healthcare professionals and that is providing the most efficacious medical treatment possible. 
Drug shortages threaten that universal purpose in several ways. Drug shortages have plagued the 
medical community for a decade or more. The Institute for Safe Medication Practices (ISMP) 
surveyed in 2010 more than 1800 healthcare professionals regarding drug shortages 1 10 The 
survey responses were: 
Little or no information available about the duration of a drug shortage (85%) 
Lack of advanced warning from manufacturers or FDA to alert practitioners to an 
impending drug shortage and suggested alternatives (84%) 
Little or no information about the cause of the drug shortage (83%) 
Substantial resources spent investigating the shortage and developing a plan of action 
(82%) 
Difficulty obtaining a suitable alternative product (80%) 
Experience a significant financial impact (78%) 
Lack of a suitable alternative product (70%) 
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Substantial resources spent preparing and/or administering the alternative products (69%) 
Risk of adverse patient outcomes (64%) 
Internal hoarding of medications associated with impending shortages (58%) 
Physician anger towards pharmacists/nurses/hospital in response to a drug shortage 
(55%).110 
The survey respondents reported: near misses as approximately 35%; actual errors due to drug 
shortages were reported at approximately 25%; adverse outcomes varied per healthcare 
professionals responding to the survey, ranging from 18-33%.110 In March of2012, the 
American Association of Anesthesiologists (ASA) surveyed 3063 anesthesiologists representing 
50 states and six nations. III Respondents reported that 67% of drug shortages had an impact on 
their patients with less than an optimal outcome; 52.8% experienced longer OR/recovery times; 
27.5% patients complained; 0.2% resulted in patient deaths (6).111 When respondents were 
asked what impact drug shortages had on his/her practice, survey results were as follows: 96.3% 
had to use altenlative drugs; 50.2% had to change the procedure in SOIne way; 7.0% had to 
postpone cases; 4. I ~) had to cancel cases. III 
Shortages have forced pharmacists, physicians and nurses in Inany hospitals to make 
contingency plans for providing safe, effective therapies when required drugs are not available. 
Additionally, drug shortages increase the incidence of drug errors.8.57,59.112 Mishaps and errors 
occur more frequently due to unfamiliarity with new agents, concentrations, and drug delivery 
1 d 8 57 II 7 E 1 . b' 'I bI 1'" b Co 'I' nlet 10 S, ' . - ven w len approprIate su stltutes are aval a e, c lnlclans may not e laml Jar 
with dosage conversions and patients nlay be over or under nledicated. 112 Emergencies pose 
even higher incidences of error due to unfamiliar drugs being utilized in fast-paced crises. I 12 
Substitute nledications can also have safety ratnifications due to substitutes being less efficacious 
d/ ' d ' k f'd f~ 8 110 113 114 M 11' f ' an or Increase ns 0 Sl e elects.' .. ore over, a oca1Ion 0 scarce resources 111 the 
form of rationing have occurred as a result of drug shol1ages. Physicians, pharmacists, and 
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clinicians have had to make difficult decisions concerning allocation of scarce resources. 
Rationing of medication has become a reality. I 14,115.116 
There are emotional elements to the drug shortages such as frustration, anger, anxiety, 
and mistrust.57,1 JO Shortages of chemotherapy medications have forced oncologists to make 
"tragic choices". Dr. Yoram Unguru, an oncologist and faculty member at the Berman Institute 
of Bioethics at 10lms Hopkins University, stated, "It was painful. We kept coming back to wow, 
we've got that tragic choice: two kids in front of you, you only have enough for one. How do 
you choose?" 1 17 Tragic choices are described by Calabresi and Bobbitt: 
Distributions of scarce goods that entail "great suffering or death," Calabresi and Bobbitt 
explain, "arouse emotions of compassion, outrage, and terror," which reveal conflicts 
between, on the one hand, the source of the scarcity and the values used to determine the 
recipients of the scarce good and, on the other hand, "those humanistic moral values 
which prize life and well-being" I 18 
Dr. Kamal Pohar, an urologist at Ohio State University's hospital, said, " I remember 
driving home, wondering if I was making the right calls for my patients." Dr. Pohar expressed 
his anxieties to the New York Times, "I can still feel the stress, I've never been faced with this 
before ".117 Another doctor at a leading hospital admitted, "We've been forced into what we 
think is a highly unethical conler, " I 17 Drug Shortages are extremely frustrating for everyone 
involved, pharmacists, physicians, nurses, and patients.8 Furthermore, professional relationships 
can be compromised when misdirected frustrations turn to anger. 8 
Government Agencies and Regulations 
The Food and Drug Administration (FDA) 
The FDA was formed in response to the 1906 Pure Food and Drugs Act. Harvey 
Washington Wiley was head of the newly founded FDA, which provided unprecedented 
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protection to consumers at that time. I 19 Through the years the FDA changed a great deal. 
Today's FDA is very cOlnplicated conlpared to its genesis in 1906. The FDA is cun"ently 
housed within the DepartInent of Health and Human Services (HHS). The HHS includes the 
Center For Drug Evaluation and Research (CDER) division. Drug shortage issues fall under 
CDER'sjurisdiction. 12o,121 
28 
In 1999, CDER developed the Drug Shortage Progrmn (DSP) with the intentions of 
Inonitoring and alleviating the ilnpact of drug shortages. 122 The GAO found that until 2011 the 
FDA did not systelnatically nlaintain data on shortages. 123 In 2011, the FDA established a 
database containing shortage infonnation. However, in 2001 due to an increase in the nUlnber of 
drug shortages (120 new shortages) the University of Utah partnered with the Anlerican Society 
of Health-System Phannacists to establish the University of Utah's Drug Infonnation Service 
(UUDIS).123,124 
In 2012, the Committee on Oversight and Government Refonn (HCOGR) presented a 
report to the House of Representatives entitled "FDA's Contribution to the Drug Shortage 
Crisis". 125 The report stated there was a dramatic drop in sterile generic drug production since 
Margaret Hamburg became commissioner. 126 Hamburg promised an aggressive enforcement 
effort to make sure that stringent manufacturing standards are met. 126 The first year Hamburg 
was in office warning letters sent to drug manufactures increased 42%.125,126 The HCOGR 
alleged that the shortages were largely due to aggressive regulatory actions by the FDA. 125,127 
FDA warning letters contained threats of legal action and seizure of products. 128,129 Letters sent 
out to manufacturers in some cases resulted in the companies halting drug production. 130,125 Four 
out of five U.S. generic injectable drug manufacturers were essentially required simultaneously 
to halt production in order to address FDA warnings. 126 The committee reported that FDA 
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regulatory activity shut down 30% of the total manufacturing capacity of four large producers of 
generic medications. 125 
Temporary closure of one manufacturing facility can lead to over burdening of other 
facilities and result in an inability to increase supply to meet the new demand. The HCOGR 
claimed that FDA warning letters increased 42% (474 to 673) between 2009-2010 and 156% 
(673 to1720) between 2010-2011. 125 However, this data is somewhat misleading. The statistics 
the HCOGR quoted is the total number of warning letters sent out from the FDA. The FDA 
statistics for warning letters exclusively from the CDER (division responsible for drugs) for 
2009-2010 increased approximately 53% (112 to 171) and in 2010-2011 warning letters 
decreased approximately 37% (171 to 108).128 CDER represented only 25.4% (171 of 673) in 
2010 and 6.2% (108 of 1720) in 2011 of the total warning letters sent out by the FDA.128 
The FDA was quick to refute the HCOGR allegation. Jeanne Ireland, FDA Assistant 
Commissioner for Legislation, wrote that the FDA was not the root cause of the drug 
shortage. 131 ,132 She stated that more than half of all the drug shortages were due to 
manufacturing quality and production problems. 131,132 FDA violations at the four largest generic 
injectable drug manufactures included the presence of endotoxins, glass and metal particulates 
contamination, aseptic manufacturing and crystal formation in injectable solutions. l33 Ireland 
also pointed out that the largest increase of warning letters in 2011 were sent to the Center for 
Tobacco Products (1040 of 1720) which accounted for 60% of the total warning letters sent out 
by the FDA. 128,l31,l32 
The Deputy Commissioner of the FDA and senior policy advisor to the Centers for 
Medicare and Medicaid Services, Dr. Scott Gottlieb, testified that outdated policies and 
inflexibility are major contributors to the drug shortage. 125 Dr. Gottlieb wrote: 
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With its vigilance heightened, the FDA has required manufacturers to undergo major 
plant renovations, suspend facilities or stop shipping goods from suspect production 
lines. The FDA and the manufacturers often don't understand the drug-production 
processes well enough to detect the root cause of problems. Instead of calling for 
targeted fixes of troubled plants, the agency has often required manufacturers to 
undertake costly, general upgrades to facilities. As a result, in 2010, product quality 
issues - and the subsequent regulatory actions taken by FDA to address these problems-
were involved in 42% of the drug shortages. 125 
The oversight committee questioned why the FDA mandated practically all of America's main 
manufactures of sterile generic injectables to upgrade facilities at the same time. 125 The HCOGR 
alleged that by forcing this remediation the FDA essentially decreased available manufacturing 
capacity by 30%.125 
The FDA has limited control over manufacturing; it cannot require a manufacturer to 
increase capacity, capability, or redundancy. 134 The FDA cannot demand that a manufacturer 
make a specific drug, maintain a specific drug inventory level, or interfere with business 
decisions to discontinue specific drug lines. 134 The FDA also lacks the authority to require 
manufacturers to provide the agency with information about potential or current shortages and 
must rely on voluntary reporting135 Furthermore, the FDA lacks the authority to impose 
penalties on companies that do not submit reports on discontinuations. 135 The FDA must 
approve all prescriptions drugs sold in the U.S. regardless of where they are manufactured. 136 
This is to ensure safety and efficacy requirements. In an interview with Drug Controller General 
of India, Dr. G N Singh stated: "If I follow US standards, I will have to shut almost all drug 
facilities" 137 Dr. Singh went on to say, "The FDA may regulate its country, but it can't regulate 
India on how India has to behave or how to deliver." 138 He added, "We don't recognize and are 
not bound by what the U. S. is doing and is inspecting," 138 
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On October 31,2011 President Obama issued an executive order expanding the FDA's 
influence. As follows: 
Executive Order 13588: 
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Sec. 2. Broader Reporting of Manufacturing Discontinuances. To the extent permitted by law, 
the FDA shall use all appropriate administrative tools, to require drug manufacturers to provide 
adequate advance notice of manufacturing discontinuances that could lead to shortages of drugs 
that are life supporting or life sustaining, or that prevent debilitating disease. 
Sec. 3. Expedited Regulatory Review. To the extent practicable, and consistent with its 
statutory responsibility to ensure the safety and effectiveness of the drug supply, the FDA shall 
take steps to expand its current efforts to expedite its regulatory reviews, including reviews of 
new drug suppliers, manufacturing sites, and manufacturing changes, whenever it determines 
that expedited review would help to avoid or mitigate existing or potential drug shortages. 
Sec. 3. Review of Certain Behaviors by Market Participants. The FDA shall communicate to 
the Department of Justice (DOJ) any findings that shortages have led market participants to 
stockpile the affected drugs or sell them at exorbitant prices. The DOJ shall then determine 
whether these activities are consistent with applicable law .... 139 
The Medicare Modernization Act 
The Medicare Modernization Act (MMA) of 2003 (implemented in 2005) has been cited 
repeatedly in the literature as a cause of the drug shortages. Basically, the MMA changed the 
formula for which Medicare and Medicaid Services (CMS) are reimbursed for Medicare Part B 
(outpatient program) drugs. 126 Before the enactment ofMMA the cost for injectable drugs that 
were administered in an outpatient settings by physicians were reimbursable on a formula based 
on the "Average Wholesale Price"(A wp).126 Oncologists prior to MMA used the "buy and bill" 
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reimbursement scheme to administer chemotherapy, which could be quite lucrative. 126 An 
oncologist buys the cancer medications, administers it to the patients and subsequently bills 
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Medicare and insurance companies for the costS. 140,141 Medicare reimbursed physicians at 95% 
of the A WP. Due to unrestricted price setting by the manufacturers, an oncologist paid 66% to 
88% of the drug price, resulting in Medicare overpayments of $1.6 billion annually. 141,142 
Former White House advisor, oncologist Ezekiel J. Emmanuel, stated that essentially Medicare 
and insurance companies were charged using made-up "average wholesale prices". 140 The 
substantial markups in reimbursement of chemotherapy drugs have been a long-standing practice 
by private oncologists. 143 Oncologists countered in a report to United States General Accounting 
Office that Medicare's payment system does not sufficiently reimburse for the cost of 
administering chemotherapy. 144 
In 2005, the implementation ofMMA changed the pricing reimbursement formula to 
average sales price (ASP) plus 6% markup to cover administrative costs. 140-142 Much of the 
literature points to the new reimbursement formula as a factor with unintended consequences that 
result in drug shortages. The MMA is referred to as a "price control" that prevents prices from 
rising in response to market changes. 141,145 Dr. Emmanuel reiterated that the MMA had 
unintended consequences of restricting price increases greater than 6% every six months. 140 A 
professor at Columbia Business School, Awi Federgruen, blamed drug shortages on government 
price controls that limit manufacturers profit margins to 6%.146 In December 2011, Patrick 
Cobb, an oncologist from Montana, testified to the United States Senate Committee on 
Finance. 147 He believes that the MMA is responsible for the consolidation of the generic 
manufacturing market and therefore it is the root cause of drug shortages. 147 Furthermore, he 
testifies that the reimbursement system that was set up by the MMA is the underlying reason that 
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drug shortages occur. 147 Reporting MMA as a root cause is limited to literature focused 
exclusively on oncology drug shortages. However, in 2011 oncology drugs comprised only 16% 
of the total drug shortages. IS A study by Evan A. Krasomil, (prepared for Senator Robert P. 
Casey, Jr) "Measuring the Impact of the Medicare Prescription Drug, Improvement, and 
Modernization Act of2003 on Shortages of Sterile Injectable Oncology Drugs,,141 found: 
Contrary to the assertions made by Emanuel and others - that reimbursement rates are 
being prevented from rising by more than 6% every six months -rates for sterile 
injectables examined here, particularly generic, commonly rose by more than 6% 
between quarters. In some cases, reimbursement rates for a number of drugs examined 
here rose by hundreds or thousands of percentage points between quarters ... 
Examination of changes in reimbursement rates following the implementation of MMA 
indicate that, contrary to what many who have written or spoken on the topic of oncology 
drug shortages state, the new rate formula of ASP plus 6 percent does not appear to be 
capping the rate at which reimbursement rates for drugs can rise. Indeed, the MMA 
formula uses the "average sale price"(ASP) of a drug to set reimbursement rates; this is a 
market driven formula dictated by the actual selling price of a drug, not- as it has often 
been characterized - a "Price control" set by the federal government. 141 
In a 2014, the GAO report to Congress regarding the impact ofMMA on the drug 
shortages was evaluated. The GAO reported that four of the five manufacturers claimed that the 
change in Part B reimbursement did not playa major role in the cause of drug shortages I23 
Additionally, it was stated that the change in Part B had a negligible effect because 
reimbursement was paid to the physicians and not the manufacturers. 123 Moreover, the 
preponderance of generic sterile injectables are utilized in an inpatient hospital setting and 
therefore not reimbursed under Medicare Part B. I23 
Drug shortages were also reported outside of the U. S. and Canada. Margaret McCartney, 
a general practitioner in Glasgow, stated in British Medical Journal (BMJ) that drug shortages 
were not only a United Kingdom (UK) problem but also a global problem. 148 McCartney went 
on to say, "This global problem needs a global solution. A stable supply of (usually) cheap 
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useful drugs should be an international priority, and if free markets can't Inanage it then we need 
a systeln that can.,,148 A survey conducted by the European Association of Hospital Phan11aclsts 
(EAHP) revealed that drug sholiages are widespread, and affect virtually every European 
nation. 149 The survey showed drug shortages throughout a11111edical categories. 149 SOll1e 
Europeans are concerned because the dlug shortages in Europe SeelTI to be 1110ving in a Olninous 
direction including 1110re critical drugs such as antibiotics, cancer drugs, anesthetics, and 
emergency medicines. 149 A 2015 study, Insights into European Drug Shortages: A Survey of 
Hospital Pharmacists, discovered a majority of the respondents identified anti-infective 
medications in conjunction with cancer drugs as being affected most by the shortages. 150 
Generic, less expensive injectables were predominant in the drug shortage categories. ISO 
Patients 
The impact of the drug shortages on patients has been well documented.22,94,ISI The 
patients have had to contend with delayed treatments, canceled surgeries, inadequate clinical 
outcomes, and increased risks including death. 94, I 10 Drugs including antibiotics, anesthetics, 
chemotherapeutic drugs, and cardiac medication are just a few of the medications that are in 
short supply. When generic drugs are unavailable, expensive brand name drugs, that are not as 
effective, may be used as substitutes. Insurance companies may not cover the substitute 
medications because they are not considered the first-line treatment. 
Patients may incur higher treatment costs due to drug shortages. Patients' clinical 
outcomes also have been affected by using replacement drugs that are not as efficacious as the 
fi 1· h 8110113 2 lrst Ine t erapy.' , In 011, at least 15 deaths and several adverse outcomes have been 
·b d h dru h 113 152 153 . . attn ute to t e g s ortage. ' , FrustratIon, anger, and betrayal penneate the lIterature 
with anecdotal accounts of personal tragedies and challenges. Mary Greene, assistant director of 
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development services at Colulnbia Law School, could not find treatment for her bladder cancer 
due to the unavailability ofBCG, a cancer medication. 154 Greene scoured the Internet until she 
was able to find isolated doses at various hospitals. Greene told the Wall Street Journal, "This 
totally took nle by surprise. It was the very first tilne I had to think about the drug cOlnpanies as 
failing the people that they're supposed to be there for.,,154 
Wholesalers/Distributors 
Wholesalers purchase drugs from manufacturers and distribute them to pharmacies 
hospitals, and other healthcare facilities. In addition, they may provide other services such as 
repackaging of pharmaceuticals and drug buy-back programs. 136 Manufactures supply 
pharmaceuticals to wholesalers and self-warehousing chain pharmacies. 136 The typical 
pharmaceutical flow through the pharmaceutical supply chain as explained by a Kaiser Family 
Foundation paper stated: 
Pharmaceuticals originate in manufacturing sites; are transferred to wholesale 
distributors; stocked at retail, mail-order, and other types of pharmacies; subject to price 
negotiations and processed through quality and utilization management screens by 
pharmacy benefit management companies (PBMs); dispensed by pharmacies; and 
ultimately delivered to and taken by patients. 155 
The wholesale market has experienced a period of consolidation, which has left three of 
the largest national drug wholesalers (AmerisourceBergen, Cardinal Health, and McKesson) with 
90% of the market share. 155 Regional and secondary wholesalers comprise 10% of the market 
share. 136 In the past, pharmaceutical wholesalers traditionally functioned to receive products 
from manufacturers, warehouse the products, and manage the inventory. 155 Today, wholesalers 
have expanded into specialty drug distribution, electronic order services, reimbursement support, 
repackaging of pharmaceuticals, and drug buy-back programs, as previously mentioned. 155 In 
the generic market, the wholesalers have more bargaining power than they do with the brand 
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pharmaceuticals. This is due to the ability of wholesale distributors to drive market share or to 
increase the volume sold. I55 The pharmaceutical supply chain is complex and the flow of money 
among various entities makes it difficult to follow the money trail. 61 There can be substantial 
disparity in the price that different purchasers pay for the same drugs. 155 
Drug shortages have created an environment that is conducive to gray markets. Gray 
markets are supply channels that are unofficial and not authorized by the original manufacturer. 
Gray markets may also be referred to as "parallel markets". 156,157 During drug shortages, 
hospitals are unable to get scarce drugs through the normal supply channels. Gray markets can 
emerge in markets where products are scarce. During drug shortages, secondary wholesalers buy 
all available drugs on the shortage list taking advantage of the opportunity to sell the drugs at 
extremely high prices. As the number of drugs in short supply increased, hospitals began 
receiving calls from secondary wholesalers that were interested in selling specific drugs (at 
inflated prices) that hospitals were unable to find elsewhere. 158 
In 2011, Premier Healthcare Alliance surveyed all of its acute-care hospitals inquiring 
about unauthorized offers to sell drugs that were in short supply. 156 Within a two week period, 
1745 examples of gray market offers were reported from 42 acute-care hospitals. 156 Of the 1745 
drugs offered, all were on backorder from the manufacturer and unavailable to hospitals through 
any other legitimate channel. 156 The largest markups were the ones needed to treat the critically 
ill patients. Figure 3 from Premier Healthcare Alliance shows drug markup versus drug/care 
categories. 156 
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Examples of 10 highest recorded markup offers by drug name, care category 
5000% a. 
::J 4500% 












Figure 3. Highest Drug Markups 156 
Findings from the House Committee on Oversight and Government Reform (HCOGR) 
reported that some injectable drugs "leak out" into gray market distributions and never reach the 
intended healthcare providers. 158 The gray market distribution consists of a number of different 
companies that buy and resell drugs to each other (with markups at each phase of the journey) 
before they reach their ultimate destination of the healthcare provider. 158 In addition, the 
HCOGR report found that: 
"Fake Pharmacies" Acquire Prescription Drugs from Authorized Distributors and then 
Sell Them Into the Gray Market ... 
"Drug Brokers" Recruit Pharmacies to Purchase Drugs for the Gray Market ... 
Gray Market Business Practices Are Widespread ... 
Gray Market Drugs Are Marked Up as They Quickly Pass from Owner to Owner ... 
Gray Market Companies Sometimes Charge Hospitals Significantly Different Prices for 
the Same Drug Product on the Same Day ... IS8 
How a Typical Drug Chain Should Work: 
hup:llden:tocrats.oversight.house.gov/inyestigatiQns/investigation-of-the-graY-lDarket 
Figure 4. How Typical Drug Chain Should Work 
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Figure 5. How the Current Drug Chain Works 
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Figure 6. Gray Market Product flow 
Figure V - "Gray Market n Shipment of 25 Vials of 2.5g/50mL Vials of Fluorouracill 
Markup = 8471% 
UGray Market" 
Pur chase Price Per Vial $7 $50 $69 $95 $275 $375 $600 
Figure 7. Example of a Fluorouracil Shipment Through the Gray Market 
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Other concerns about gray market drugs relate to the safety of the products. Due to the 
unpredictable path the injectable drugs follow, it would be impossible to know if the drugs were 
stored or handled appropriately. The Fox Chase Cancer Center in Philadelphia told the HCOGR 
committee, "If I can't be absolutely sure of the integrity of the drug, then I can't administer it to 
a patient.,,158 A drug from the gray market doesn't have the same quality assurance; there is no 
way to insure a drug's legitimacy or its pedigree. The FDA describes a drug pedigree as: 
A drug pedigree is a statement of origin that identifies each prior sale, purchase, or trade 
of a drug, including the date of those transactions and the names and addresses of all 
parties to them. Under the pedigree requirement, each person who is engaged in the 
wholesale distribution of a prescription drug in interstate commerce, who is not the 
manufacturer or an authorized distributor of record for that drug, must provide to the 
person who receives the drug a pedigree for that drug. 159 
Making the gray market drug problem even riskier is the possible introduction of 
counterfeit drugs into the gray market drug distribution chain. Counterfeit drugs are defined as 
drugs that may not have active ingredients (AI), may have too much or too little AI, wrong AI, or 
fake packaging. 160 According to the FDA, there is a greater chance of introducing counterfeit 
drugs into the supply chain when there are multiple wholesalers. 161 Primary and regional 
wholesalers work directly with manufacturers and are not usually a source of entry for 
counterfeit drugs. 162,163 Conversely, secondary wholesalers buy and sell drugs based on market 
shortages and surpluses. 162 Secondary wholesalers do not work directly with manufacturers. 162 
They also package and repackage drugs thus providing opportunity for the introduction of 
counterfeit medications into the system. 162 It has been reported that 40% of all drugs in the U.S. 
are made overseas. 160 In addition, 80% of all active ingredients for drugs are imported from 
foreign manufacturers located in more than 150 countries. 164 Rogue wholesalers have found 
ways to exploit the system to manipulate their way into the distribution chain. In addition to the 
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harmful affects on patients, the counterfeiters are able to exploit healthcare systems and patients 
by charging exorbitant prices. 162 Counterfeit drugs have increased the cost of healthcare while 
endangering the lives of patients. The drug shortages have encouraged the influx of counterfeit 
prescription drugs into the United States. 
Insurance Companies 
A literature research review considering insurance companies' role in the drug shortages 
did not expose any direct or indirect association. However, insurance companies may affect the 
patients' access to affordable medication since the insurance companies may not pay for 
alternative therapies. 165 Increased cost for substitution drugs mayor may not be covered by 
third-party payers. According to a survey by the National Community Pharmacists Association 
(NCPA), 520/0 of respondents reported that insurance companies do not cover alternative 
treatments and the patient bares the brunt of paying for the substitute drugs. 165 The survey 
respondents reported that 66% of patients go without their prescribed drugs as a result of the 
drug shortage. 165 
Raw Material Suppliers 
The American drug supply chain is complicated and dependent upon a global supply of 
raw materia1.60,61 Drug manufacturers may be reliant on a single supplier of an active ingredient 
for a particular drug. 8, 123 While there may be multiple manufacturers making the same 
medication, the dependence on one source for raw material makes the upstream supply chain 
tenuous.8,160 Quality control presents a challenge due to the vast number of outsourced suppliers 
located in hundreds of foreign countries. 123,160 Testimony to the GAO manufacturer 
representatives stated that the unavailability of raw material or AI has been the cause of some 
drug shortages; however, it was a small percentage.123 FDA data analysis revealed that between 
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2011-2013 unavailability of raw material accounted for 9% (see Figure 8) of drug shortages. 123 
Figure 8. Reported Causes of Drug Shortages from January 2011 through June 
2013 
Source· GAO analysis of FDA data. 
loss of manufacturing site or site change 
Increased demanda 
Active pharmaceutjcal ingredient (API) or 
non-API component Issueb 
Product discontinutation 
Manufacturing delays and capacity issuesc 
Quality problemsd 
Figure 8. Causes of Drug Shortages January 2011 Through June 2013 
Erin Fox, Director Drug Information Service University of Utah Healthcare, in a presentation 
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focusing on drug shortage "Myths vs. Reality" stated that unavailability of raw material is rarely 
the cause. 166 Raw material shortages may be due to numerous factors, including political 
conflicts, natural disasters, environmental factors, trade disputes, and degradation or 
contamination during transport.8 Packaging components and repackaging problems could also 
interfere with the supply of available raw material. However, after extensive research, it does 
not appear that the lack of raw material is a major factor in drug shortages?8,166 
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Methodology and Study Design 
This qualitative explanatory paper attempts to clarify conditions that have led to critical 
drug shortages in the U. S. Stakeholder analysis and evaluation of the pharmaceutical market 
environment are the primary tools used to examine market behavior. These are examined in three 
stages: 
1. Information collected by reviewing literature, white papers, interviewing subject-matter 
experts and examining government agency reports. The research concentrates on information 
regarding what is known about the drug market environment, market behavior and stakeholder 
involvement. Stakeholders' interests and positions via "stakeholder analysis" in relation to the 
generic drug shortages are examined. 
2. Each stakeholder's position is compared to established economic theories to shed light upon 
its role and possible contribution to the generic drug shortage crises. 
3. Findings of the stakeholder analysis and market evaluation are summarized and added to the 
conclusion section, thus forming a clearer explanation of the drug shortage. 
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Conceptual Framework: 
u.s. Drug Shortages: Stakeholders' Analysis and Market Evaluation 
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Figure 9. Conceptual Framework: U.S. Drug Shortages: Stakeholders' Analysis and Market Evaluation 
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Results 
Material accumulated from the literature review and stakeholder analysis fell into four 
categories. Primary effects are factors that are stated to directly impact drug shortages. 
Secondary effects do not directly impact drug shortages; however, they exacerbate existing drug 
shortages. Safety issues are unsafe conditions created by stakeholders or drug shortages. 
Consequences of drug shortages are conditions that are created as a result of the drug shortages. 
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After an extensive literature review, government reports, subject expert testimonies, and 
interviews, four of the nine stakeholders fell into the "Primary Effects" category. In Table 1, 
drug manufacturers, government agencies' regulations, GPOs, and raw material suppliers are 
cited most often as a primary or a root cause of the sterile injectable drug shortages. Of the four 
stakeholders designated as primary causes of drug shortages, drug manufactures were most often 
cited as the root cause. Over-aggressive government agencies' regulations and enforcement 
activities are cited for shutting down or holding up production at drug manufacture sites. GPO 
research material lacked empirical support, however, it was frequently cited as a root cause. 
Lack of raw material is named least often as a root cause of the sterile generic drug shortages. 
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Review of the literature placed drug manufactures, healthcare facilities, and wholesaler 
distributors in the "Secondary Effects" category. The JIT inventory process was asserted to 
exacerbate shortages in both manufacturing and healthcare facilities. While stockpiling, hoarding 
and diverting are attributed to secondary wholesaler distributors. When first line drugs are 
unavailable, healthcare facilities inadvertently cause secondary drug shortages of substitute 
drugs. Business decisions focus on opportunities that yield better profit margins exacerbating 
drug shortages by producing less or eliminating drugs in short supply. 
The "Safety Issue" category includes both stakeholders that cause the safety issue and 
stakeholders that are affected by the safety issue. Eight of the nine stakeholders are associated 
with safety issues. Patients are the only stakeholders that are exclusively affected by safety 
issues. The other seven stakeholders are contributing causes of safety issues. Safety issue 
conditions may be inadvertent, unintended, or forced on stakeholders. However, stakeholders 
are responsible for safety issues that originate in their domain. Only the GPOs were excluded 
from the "Safety Issue" category. 
As a result of drug shortages several ancillary conditions developed. While these 
conditions do not playa role in the root cause of drug shortages they have a significant affect on 
stakeholders and the market environment. Five stakeholders are assigned to the "Consequences 
of Drug Shortages" category. Manufactures are responsible for supplying the market with 
generic drugs. As a result of the industry's inability to fulfill that obligation several conditions 
have developed such as the expansion of compounding pharmacies, gray markets, and increased 
opportunity for counterfeit drugs to enter the supply chain. Healthcare facilities have incurred 
significant expenditures relating to the procurement, management of alternative therapies, 
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increased stocking and wastage cost (stockpiling and hoarding), and the use of compounding 
pharmacies when other choices are unavailable. 
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Clinical situations that are less than optimal expose healthcare professionals to emotions 
such as increased anxiety, frustration, anger, and mistrust. Drug shortages place healthcare 
professional in circumstances that are clinically substandard. Patients incur treatment delays, 
cancelled surgeries, and increase cost as a result of drug shortages. As a result of drug shortages, 
secondary wholesaler distributors use drug shortages to their advantage by procuring and 
diverting drugs that they eventually sell at significantly increased prices. 
Discussion 
Why are there so many drug shortages in the U. S.? The answer is complex and involves 
many factors. F our out of nine stakeholders are reported as primary causes of the drug 
shortages. Particularly, Drug manufacturers, government agencies' regulations, GPOs, and raw 
material suppliers are cited most often as "primary or a root causes" of the sterile injectable drug 
shortages. 
Drug manufacturers 
Stakeholder investigation of generic drug manufacturers as the source of drug shortages 
appears like a logical place to begin. Information collected about generic drug manufactures can 
be classified into four different categories: Primary Effects, Secondary Effects, Safety Issues, 
and Consequences of Drug shortages (Table 1). 
The generic drug market in 2013 was valued at $168 billion and expected to reach $283 
billion by 2018 growing at a cOlnpound aIu1ual growth rate (CAGR) of 11 %.167 The majority 
(80%) of shortages are concentrated in the sterile injectable generic market despite the fact they 
comprise only 29% of the entire generic market.s It is interesting to note that these sterile 
WHY SO MANY DRUG SHORTAGES 51 
injectables are older drug products and have very low profit margins. The demand for these 
drugs remains steady and is the foundation of many clinical specialties. Market forces apply 
downward pressure on the prices of these generic drugs. Market forces include GPOs, 
government policies, insurance reimbursement plans, intense competition among generic 
manufactures, and large healthcare systems' buying practices. A declining supply of a drug does 
not necessarily result in an increase in price of that respective drug. The generic market 
historically has been relatively unresponsive to price changes. 1,168 
Intense competition for big institutional contracts with group purchasing organizations 
(GPOs) has caused many generic companies to commit to long-term agreements. Moreover, the 
conditions of the generic manufacturing facilities have been described as timeworn with need of 
updating.25 When unanticipated interruptions of production occur and a facility is already 
operating at capacity without redundancy, there is little chance of increasing capacity to meet 
unanticipated demand. With a limited number of manufacturers supplying a specific generic 
injectable, when one manufacturer develops a problem, it is not possible for the other 
manufacturers to make-up the manufacturing shortfall. Due to low profit margins, there is no 
incentive for other manufacturers to "fill the gap" between supply and demand. Long-term 
contracts make it impossible for the manufactures to increase drug prices; thus, short-term 
adjustments are difficult or nearly impossible to make under uncertain circumstances. 
It is well documented that the generic companies have limited capacity.21,25 The generic 
pharmaceutical subsector lacks the capacity to manufacture both the older less expensive generic 
drugs and newer more profitable drugs under these competitive circumstances. 14 Management 
makes business decisions based on allocating resources so that profit maximization is in the best 
interest of the company. When newly off-patent drugs become available, the generic companies 
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are faced with difficult decisions. The strategy to capitalize on the newly patent-free blockbuster 
drugs has the generic companies eliminating older generic lines that have been manufactured for 
decades. When decisions to narrow product lines are made and discontinuation of less profitable 
sterile generic injectable are eliminated from the portfolio, the market is often left with one 
supplier of the those medications. 
Consolidation has been noted in the sterile injectable generic market with only seven 
primary manufactures and with the top three accounting for 71 % of the market. It is not unusual 
to see consolidation take place in mature markets; however, the hyper-consolidation in the sterile 
injectable generic sector has many in the medical field concerned. Recently there have been 
isolated price increases of some older generic drugs.46,47 These significant increases occurred 
when there is only one manufacturer supplying a specific drug. When only one supplier is 
producing a sterile generic injectable drug, a monopoly situation may exist if no substitutes are 
available for that drug. This gives the manufacturer monopoly power over that specific drug. 
While some price increases may be the effect of drug shortages and hyper-consolidation, 
the New York Times reported that price increases may be the result of a business strategy of 
acquiring old neglected drugs and selling them as high-priced "specialty drugs".49 A new 
business strategy to make unprofitable products profitable is not unusual. However, when 
ethical and moral norms are compromised, it is extremely unpopular and controversial. I 18,169 Is 
the market attempting to equilibrate? The manufacturer increases the profit margin to such a 
degree that other manufactures enter the market, thus creating competition and putting 
downward pressure on prices until the market reaches equilibrium. This is the way the market is 
expected to work over the long run. Market forces are not sensitive to peoples' health, ethical 
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and moral obligations, and emotions. This is one reason the market is unable to equilibrate on 
its own. 
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It is well documented that quality is a major factor in the current drug shortages. 18,23 It is 
difficult to understand why such an exacting manufacturing industry does not have tight quality 
control systems. The evidence is clear that the generic pharmaceutical industry is lacking good 
quality control. Installing tight quality control processes may initially increase the cost of doing 
business. However, to avoid civil and criminal fines, increasing quality control is a necessity. 
While a tighter quality control process will decrease the number of legitimate errors missed, it 
may increase the number of inappropriately identified errors, which will also increase the cost of 
doing business. This may be a challenge for generic pharmaceutical companies due to such low 
profit margins on their products. Under these market conditions it is not surprising that 
manufactures are unable or unwilling to invest in new equipment and quality control systems to 
meet the FDA's Current Good Manufacturing Practices (CGMP). 
Government Policies and Regulations 
The pharmaceutical industry is heavily regulated. One purpose of government regulations 
is to protect consumers from the abuse ofa firm's market power. The FDA regulates food and 
drug producers placing emphasis on purity, labeling, and product safety. If this is the case, then 
why is a heavily regulated industry having major difficulties meeting and sustaining quality 
control? One possibility that may explain this situation is that regulations are not being enforced 
appropriately. Another explanation is that regulations do not ensure quality outcomes. It is also 
possible to have a combination of both, inappropriate enforcement and ineffective regulations. 
The literature suggests that it is the combination that is most likely. Over-regulation that is too 
restrictive will have negative economic consequences on the industry as a whole. Inflexible, 
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outdated regulations that are not updated and revised can impose unnecessary burdens on the 
regulated industry in question. 
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With globalization of the phannaceutical industry, it is virtually ilnpossible for the FDA to 
exert its regulatory power over 150 countries that supply the phalTIlaceutical industry. Many of 
these countries function with less sophisticated manufacturing and regulatory systems. This 
presents a conflict since the U.S. generic drug nlanufacturers outsource Inany different drug 
components to foreign suppliers. This includes 300,000 foreign facilities that expo11 FDA-
regulated products to the U.S .. 164 The FDA has not kept up in the globalization Inovement and 
does not have nlethods, authority, or resources to function in this new environlnent. 61 The GAO 
in 2009 estinlated that it would take nine years for the FDA to inspect all the foreign companies 
on the list. 17o The list of conlpanies and facilities has grown since 2009. According to FDA 
data, drugs were nlanufactured in 1110re than 100 countries in 2009 cOlnpared to 150 countries in 
2013. 170 Due to lack of FDA resources, the foreign sector supplying the generic drug 
Inanufacturers lacks oversight and is under regulated. 
Since dnlg shortages are not unique to the U.S., it seelns appropriate to develop sOlne fonn 
of global partnership to nlanage and mitigate the unchat1ed waters of regulated globalization of 
the pharmaceutical industry and its supply chain. Due to loose control over foreign contractors 
and questionable quality control at generic manufacturing sites, there have been many mishaps 
and drug recalls. This produced a knee-jerk reaction froln the U.S. govenlnlent and the FDA. 
[ncreasing oversight, the FDA focused on the sterile generic drug Inanufacturers. This activity 
essentially halted production in four out of the five Inajor generic dnlg Inanufacturers. This 
action decreased production capacity 30% for the entire sterile generic phannaceuticallnarket. 
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Appropriate regulatory oversight is imperative. As shown in the U.S. and global drug market, 
either too much or too little regulation can have devastating and far-reaching effects. 
Another important component of FDA regulations is the efficiency of the regulations 
themselves. It has been suggested that the FDA regulations and enforcenlent methods are rigid, 
unbending, and out-of-date. Good manufacturing regulations when followed by the drug 
nlanufacturer should produce a quality product. Regulations should add value to the product and 
process. This should not be a burdensome procedure that only increases the cost of production 
without ensuring an increase in quality. The U.S. generic drug industry seems to have a plethora 
of regulations without the concurrent increase in quality. Regulations need to be evaluated and 
updated to nleet the needs of a changing industry. As all industries tighten their belts and 
become more efficient in order to survive in today's competitive envirorunent, it is essential that 















Figure 10. FDA Global Manufacturer Suppliers Under-Regulation vs. FDA Generic Manufactures Aggressive Regulation 
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Sometimes governments place limits on how prices are allowed to increase or decrease 
and these mandates can affect market equilibrium.7 Government regulations that control the 
price of a product and do not permit the price to increase as demand increases will result in a 
product shortage. 171 The Medicare Modernization Act (MMA) has been reported in the literature 
as government "price control" that has resulted in drug shortages. Interestingly after researching 
and reviewing many articles, one common theme emerged. Only articles regarding 
chemotherapy drugs seem to make this allegation. Chemotherapy shortages comprised only 16% 
to 28% (2009-2014) of the total drugs involved in the shortages. What about the other 72% to 
84% of drugs reported in the shortages? Why has MMA not been as a root cause for the 
majority of all sterile generic injectable drug categories in short supply? 
Medicare Modernization Act part B is warranted in an outpatient setting. This is an 
important piece of the puzzle. Sterile injectable drugs for the most part are utilized in an 
inpatient setting such as hospitals and other inpatient facilities. The exception to this is 
chemotherapy medications, which are administered by an oncologist in an outpatient setting. 
Basically, MMA part B only affects oncologists, which explains why it was found only in 
oncology focused literature. Prior to MMA, oncologists were buying chemotherapy drugs at 
discounted prices while charging marked-up wholesale prices to Medicare. This was quite 
lucrative for the oncologist and had been the standard practice for many years. When MMA 
changed the reimbursement payment to the average sales price plus 6% oncologists lost a 
significant amount of income. This did not affect manufactures reimbursement. It is difficult to 
see how this can be considered price control. 
The fact that chemotherapy drugs are scarce in Europe and other countries that are not 
affected by U.S. reimbursement policies also infers that MMA is not the cause of drug shortages. 
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The drug shortage time line does not support MMA as a cause of drug shortages. The MMA was 
implemented in 2005. hl 1999, CDER developed the Drug Shortage Program and in 2001 due to 
an increase in the nUlnber of drug shortages (120 new shortages) the University of Utah 
partnered with the Anlerican Society of Health-System Pharmacists to establish the University of 
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Figure 11. New National Drug Shortages January 2001 to March 31, 2015 
There are additional changes in reimbursement that do not support MMA as a root cause. 
ill 2012, Congress mandated a budget sequester that Medicare Part B be cut by 2%.172 Since 
2012, oncologists have been reimbursed at ASP plus 4.3% (down from 6%).172 IfMMA is a root 
cause of chemotherapy drug shortages, one would expect that a decrease in reimbursement 
would exacerbate the chemotherapy drug shortages. That is not the case as shown in Figure 12. 
When comparing 2011 (6.0% reimbursement) to 2012 (4.3% reimbursement) there was a 58% 
decline in chemotherapy drug shortages. ill 2011 compared to 2013, there was a 73% decrease. 
When 2011 is compared to 2014, a decrease of 62% is noted. Consequently, MMA as a root 
cause of drug shortages, including chemotherapy drugs, cannot be substantiated. 
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Figure 13. National Sh0l1ages vs. Chemotherapy Shortages January 2001 to September 9, 2011 
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GPOs 
Confusion, controversies, and accusations permeate the literature, expert witness 
interpretations, and government hearings. Even the number of GPOs in existence is 
questionable. Some sources claim that there are 600-900 GPOs in operation and others claim 
that the GPO market is consolidated with only a small number controlling 85-90% of the market. 
The explanation for the great disparity in numbers seems to be that regional and local GPOs 
belong to parent national GPOs. Of the six largest GPOs, four are private and two are publicly 
held. There is little doubt of the aggregate buying power of the GPOs. The tremendous buying 
power has come into question in the procurement of generic sterile injectable drugs. GPOs use 
the principle of economies of scale to negotiate lower prices for its members. Small generic drug 
manufactures may be excluded because they cannot produce the economies of scale needed by 
the GPOs. This is perceived as an exclusionary practice and anti competitive behavior. This 
buying practice may have caused market consolidation by eliminating small sterile generic drug 
manufacturers. This consolidation contributes to the vulnerability of the sterile generic supply. 
GPOs put downward pressure on the drug manufacturers to obtain the lowest price on the 
sterile generic injectables. Once the prices are locked in long-term contracts, they become sticky 
and are not able to fluctuate with supply and demand. With incumbent GPOs enjoying the large 
market share and long-term member contracts, it is difficult to break into the GPO market. 
Additionally, the drug companies manufacturing sterile generic injectables are also concentrated. 
Long-term contracts to supply incumbent GPOs inhibit new entries into the GPO market. With 
economies of scale that have already been established, it is challenging for new companies to 
gain market share. Loyalty schemes, strong brand names, and long-term relationships among 
GPO market leaders discourage new entrants into the market. Hence, barriers to entry are high. 
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It appears that GPOs do exert some monopsony power because suppliers of generic drug 
manufactures have very little choice but to sell to one of the few major GPOs that supply 85 to 
90% of the market. Without a contract with a major GPO, a generic sterile injectable drug 
manufacturer does not have a market to sell its product. The GPO leverages that power to drive 
down the price of the sterile generic injectables. Driving prices down to benefit consumers, 
hospitals, insurance companies, and governments appears to be a worthy goal. However, the 
very low profit margins on generic sterile injectables may have unintended consequences that 
contribute to the national drug shortages and stimulate considerable consolidation of the sterile 
generic market. 
Raw Material Suppliers 
There are few industries that have not been touched by increasing globalization and the 
pharmaceutical industry is no exception. However, globalization of raw material has presented 
a few challenges to the pharmaceutical manufacturers. Tracing the route that pharmaceuticals 
take from raw material all the way to the end-user is complicated. Weaknesses in the supply 
chain with poor transparency, tainted, expired, or counterfeit drugs that enter into legitimate 
distribution channels can damage reputations and more importantly cause harm. 173 
Several misadventures in the upstream supply of raw material have led the FDA to 
concentration on security and safety issues related to the drug supply chain. In 2008, corrupted 
raw material imported from China was used in the manufacturing of heparin, a widely used 
blood thinner. The tainted raw material was implicated in the death of 81 people and injured 
another 785 reported by the FDA.174 The heparin recall affected over 10 countries. The Supply 
Chain Security Act (DSCSA) of 20 13 tnandates steps to be taken in order to build "an electronic 
interoperable systenl to identify and trace certain specific drugs as they are distributed in the 
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United States. ,,173 The DSCSA will be implemented over a period of 10 years. 175 The track and 
trace portion of the DSCSA is a requirement and responsibility of the entire supply chain. In the 
past, manufacturers only needed to ask the name of the raw material from suppliers. 176 This was 
considered enough for "source" identification. 176 The DACSA holds manufacturers fully 
responsible for the raw materials that go into their products. 176 The DACSA mandates that by 
2017 manufactures must serialize and place unique identification nUlnbers on dnlg packaging. 173 
By law, wholesalers will not be able to accept products that do not meet the serializing 
identification nUlnber protocol. 173 Managing and balancing the supply chain of custody will be 
challenging and expensive. Only the future will tell whether DACSA will strengthen the supply 
chain and eliminate its weaknesses. Raw nlaterial shortages account for only 9% of the drug 
shortages averaged over three years. However, this attention has highlighted vulnerabilities in 
the supply chain. Figure 14. Exhibits primary root causes and how they contribute to quality 
issues. 
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Healthcare Facilities 
Both vertical and horizontal consolidation trends in the healthcare market are well 
documented. 86,177 Consolidation does not appear to play an important factor in the sterile generic 
drug shortages. Increasing market share by consolidating hospital systems fosters a 
corresponding increase in market buying power. However, most hospitals do not acquire 
pharmaceuticals directly from the manufacturers; they use GPOs to negotiate the best prices. 14 
Through GPOs the hospital systems have a tremendous amount of buying power since a small 
number of GPOs control 85 to 90% of the market, as previously discussed. 14,28,68 
Inventory practices such as just-in-time may intensify drug shortages by decreasing the 
buffer a hospital has against any disruption in the supply chain. This is a secondary affect and 
not a factor in the original root cause. 
Stockpiling is associated with causing artificial shortages and draining the supply 
chains.59,178 In industrialized countries during stable economic periods, it is expected that 
scarcity of commodities will be rare. 179 "Hoarding exists when consumers' current inventory of 
an item exceeds its inventory in previous periods while the expected consumption rate remains 
constant,,179 The biggest threat is consumers' concerns and overreaction. The pharmaceutical 
industry agreed that it would not be able to keep up with demand if consumers started hoarding 
and panic buying. 180 The Vice President at McKesson Corporation warned, "If people believe 
there will be a disruption, then there will be a disruption." ... "People react out of their 
perceptions and create reality," 1 so The nlere nlention of a shortage can actually cause panic 
buying and hoarding; thus creating an artificial shortage. Overbuying and stockpiling of dnlgs 
by hospital phannacies Inay in sonle instances create secondary shortages. By atnassing a large 
atnount of inventory in anticipation of increased denland of substitute drugs, hospitals Inay 
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actually cause drug shortages of substitute medications. In addition, ordering excessive anlounts 
of drugs that are in Sh011 supply can exacerbate the probleln by causing distributive inequities. 
COlnpounding phannacies do not playa role in creating drug shortages. Some argue that 
they actually help by providing an alternative to cOlnmercial drug nlanufacturers. The 
Association of State and Territorial Health Officials (ASTHO) suggests that compounding 
pharmacies have been singled out as a means to increase drug availability during the 
shortages. ] 8 I While the potential to lessen the impact of the drug shortages is possible by 
utilizing compounding pharmacies, the lack of FDA oversight and historical mishaps make using 
compounding pharmacies a risky venture. The Drug Quality and Security Act (DQSA) enacted 
November 27,2013 established opportunities for large-scale outsourcing facilities that 
compound sterile drugs to voluntarily register and be subject to FDA oversight. 182 However, 
compounding pharmacies will continue under the oversight of the state boards, which will strive 
to increase communication between federal and state entities. 182 
Healthcare Professionals 
There is no doculnentation in the literature that supports or inlplies that healthcare 
professionals contribute to the root causes of drug shortages. Documentation suggests that 
healthcare workers suffer elnotionally due to added stress. Ethical dilelnmas related to the 
allocation of scarce resources that detennines life and death place healthcare professionals in an 
insufferable position. Drug shortages impact the healthcare professionals' ability to deliver 
quality healthcare. With scant options due to drug shortages, choices are made to use expensive 
altenlatives that mayor lnay not be as effective. Therefore, healthcare professionals may 
unwittingly, given the limited therapeutic choices, raise the cost of health care. 
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Wholesalers Distributors 
Wholesalers playa fundamental role in the sterile generic drug supply chain. There is no 
supporting evidence that wholesalers playa major role in drug shortages. Although, the 
development of gray markets may exacerbate the drug shortages. By diverting drugs from the 
principal-users to secondary wholesalers and fake pharmacies, the drugs reside in the supply 
chain longer and may need to be disposed of due to limited shelf life. By delaying drugs from 
getting to the end-users and increasing drug wastage, the gray market exacerbates the drug 
shortages on two fronts while also increasing the cost of health care. Many end-users do not buy 
drugs from gray market wholesalers because the drug pedigree cannot be verified. Without a 
proper pedigree, the drugs legitimacy cannot be substantiated. 
Three conditions must exist for gray markets to develop.183 First, the gray market must 
have a supply source. 183 Second, barriers must be low enough to move products from one supply 
route to another. 183 Third, price differentials must be large enough to provide incentives for gray 
marketing. 183 All three of these conditions are met by the current drug shortages. Network 
wholesalers monitor the market looking for indications of new drug shortages. They monitor 
trade and government web sites and watch for maj or recalls with the intention of buying as much 
as possible of a drug in short supply. 184 Once they acquire the scarce medication, they stockpile 
and hoard the medication that they will later sell at inflated prices. Weakness and loopholes in 
the supply chain present low barriers to gray market profiteers allowing gray market medications 
to leak into the drug supply chain. The drug shortages provide profit-making opportunities for 
gray market profiteers. Some refer to the profiteers as "price gougers" and "scalpers".158 An 
article in the Canadian Medical Journal titled: "Prices Gone Wild: Grey Market 'Scalpers' 
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Scoring Windfall in American Drug Market" stated that there is no federal law against price 
gouging. 185 
Patients 
The impact of the drug shortages on patients has been well documented.22,94,151 The 
patients have had to contend with delayed treatments, canceled surgeries, inadequate clinical 
outcomes, and increased risks including death. 94,11 0 Patients' clinical outcomes also have been 
affected by using replacement drugs that were not as efficacious as the first line therapy.8,110,113 




Health insurance companies do not playa major role in the root causes of the drug 
shortages. The economic impact is focused primarily on the patient with healthcare systems also 
absorbing costs for alternative medication not covered by insurance companies. However, health 
insurance may playa role in contributing to drug price inelasticity. Health insurance limits 
consumers' incentives to be concerned about costs associated with the use of medical services. 186 
Insurance coverage lowers an individual' s risk and consequently increases the denland for 
pharnlaceuticals. By spending sonleone else 's nloney for drug purchases, individuals become 
less price sensitive. Consumers also lack the appropriate knowledge to make sound economic 
and medical decisions. 186 
Conclusion 
The U.S. is a leader in technology, finance and business, entertainment and higher 
education. The U.S. has drugs that can treat erectile dysfunction, grow longer eyelashes, and 
paralyze muscles to prevent wrinkles. However, many drugs that are medically necessary to 
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treat life-threatening illnesses are in short supply. Why? Understanding the problem and all its 
complexities is the first step. Economic and stakeholder analysis is the key. The overlapping 
relationships of the four stakeholders that are identified as "primary" root causes of the drug 
shortages are complicated. The market will not recover on its own due to non-market forces, 
normative ethics, moral obligations, and human emotional factors. The new question becomes 
what adjustments need to be implemented that will solve the drug shortage problem without 
upsetting and distorting the generic market even more. There is not a quick fix. While solutions 
will take time to emerge, mitigation of "secondary effects", "safety issues", and "consequences 
of the drug shortages" can alleviate some of the symptoms but will not cure the sick market. 
The drug shortages are unlikely to resolve in the near future. The FDA, drug 
manufacturers, and healthcare facilities are doing what they can to mitigate the impact of drug 
shortages. The roots causes are complicated and not easily remediated. Future research should 
focus on how to incentivize manufacturers to produce older sterile generic drugs. Generic drug 
manufacturing companies have a fiduciary responsibility and obligation to make a profit thereby 
increasing the wealth of the shareholders. Making these drugs profitable is the only way that 
private companies can rationalize producing these older generic drugs in lieu of other profit 
making opportunities. 
Government subsidies, tax breaks, and other incentives should be explored. Increasing 
supply by extending shelf life should also be investigated. A FDA study found that as many as 
90% of drugs were still efficacious after their expiration dates. 187 Many of these drugs were 
found to be safe and effective years after the manufacturer's expiration date. One drug was 
found to be as effective 15 years after the expiration date. 187 Globalization is a theme that keeps 
recurring throughout this study on drug shortages. Perhaps more effort should be focused on a 
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global solution since drug shortages seem to be a global problem. Organizations such as the 
World Health Organization (WHO) or the United Nations (UN) should make an effort to unite 
and explore joint solutions to the mutual problem of drug shortages. 
Limitations of this paper are as follows. The research is based on data that is dynamic 
and in many cases subjective. Minimal empirical data was available for analysis. Analysis, 
opinions, and conclusions are based on information that was accessible at the time. As drug 
shortages evolve, new information continues to become available enhancing awareness and 
shedding light onto the drug shortage problems. Continued research is essential to move 
forward. 
68 
WHY SO MANY DRUG SHORTAGES 69 
Bibliography 
1. Koh H. Testimony of Dr. Howard Koh. Washinton DC: US House of Representatives; 2011. 
Examining the Increase In Drug Shortages. 
2. Hamburg MA. Report to Congress: First Annual Report on Drug Shortages for Calendar 
Year 2013: Food and Drug Administration; 2014. First Annual Report on Drug Shortages. 
3. White House. Executive Order 13588 -Reducing Prescription Drug Shortages: White 
House; 2011. Executive Order 13588. 
4. Kweder S. Prescription Drug Shortages: Examining a Public Health Concern and Potential 
Solutions. FDA.gov. December 15,2011. Available at: 
http://www.fda.govlNewsEvents/Testimonylucm282956.htm. Accessed February 12,2016. 
5. Food and Drug Administration. Introduction and Background Table of Contents: A Review 
of FDA's Approach to Medical Product Shortages. FDA.com. November 3,2011. Available 
at: 
http://www.fda.gov/AboutFDAIReportsManualsForms/Reports/ucm277745.htm#characteri 
stics. Accessed February 26,2016. 
6. FDA. Text Version: Drug Shortages Infographic. FDA.com. April 7, 2011. Available at: 
http://www.fda.gov/Drugs/DrugSafetyiDrugShortages/ucm441585.htm. Accessed June 12, 
2015. 
7. Baye MR. Managerial Economics and Business Strategy. Fifth ed. New York: McGraw-
Hill Irwin; 2006. 
8. Ventola CL. The Drug Shortage Crisis in the United States Causes, Impact, and 
Management Strategies. Pharmacy and Therapeutics. 2011;36(11):740-757. 
9. Chisholm-Burns MA, Vaillancourt AM, Shepherd M. Pharmacy Management, Leadership, 
Marketing, and Finance. Vol 1. 2nd Edition ed. Burlington: Jones & Bartlett Learning; 
2014. 
10. Gwartney JD, Stroup RL, Sobel RS, Macpherson DA. Economics Private and Public 
Choice. 14th ed. Mason: Cengage Learning; 2013. 
11. Kantarjian HM. When the drug you need to cure a cancer is nowhere to be found. The 
Washington Post. April 18, 2011. https://www.washingtonpost.com/nationallhealthlwhen-
the-drug-you-need-to-cure-a-cancer -is-nowhere-to-be-
foundl2011104/111AFH802zD story.htm!. Accessed july 3,2015. 
12. Kaitin KL. The landscape for Pharmaceutical Innovation: Drivers of Cost-Effective Clinical 
Research. Pharm Outsourcing. August 2011. 
13. DeRuiter J, Holston PL. Drug Patent Expirations and the "Patent Cliff'. US Pharmacist. 
June 2012;37(6). 
14. Haninger K, Jessup A, Koehler K. Economic Analysis of the Causes of Drug shortages: 
United States Government; 2011. ASPE issue Brier. 
15. IMS INSTITUTE for HEALTHCARE INFORMATICS. Drug Shortages: A closer look at 
products, suppliers and volume volatility: IMS INSTITUTE for HEALTHCARE 
INFORMATICS; 2011. Drug Shortages: A closer look. 
16. Selyukh A. Study finds U.S. drug shortage problem concentrated. Reuters. November 14, 
WHY SO MANY DRUG SHORTAGES 
2011. http://www.reuters.comJartic1e/2011111114/us-drugs-shortages-imshealth-
idUSTRE7AD1CJ20111114. Accessed August 20,2015. 
70 
17. Hill JM, Reilly C. Can the United States Ensure an Adequate Supply of Critical Medicatios? 
Publication of the Food and Drug Law Institute. August 2011;1(16). 
18. Shelley S. The quality improvement drive to address shortages. Pharmaceutical Commerce. 
January 28,2015. 
http://www.pharmaceuticalcommerce.com/index.php?pg=manufacturing and packaging&a 
rtic1eid=27458&keyword=drug%20shortages-manufacturing%20quality%20problems. 
Accessed August 21, 2015. 
19. Lee SB. The Drug Sjhrotage Crisis: When Generic Manufacturers" Just Say No". Oregon 
Law Review. 2014;93:355. 
20. Gottlieb S. Drug Shortages: Why they happen and what they mean. Washington, DC: 
American Enerprise Institude; 2011. Statement before the Senate Finance Committee. 
21. Fox ER, Sweet BV, Jensen V. Drug Shortages: A Complex Health Care Crisis. Mayo Clinic 
Proceedings. March 2014;89(3):361-373. 
22. Orlovich DS, Kelly RJ. Drug Shortages in the U.S. - A Balanced Perspective. Journal of the 
Anesthesia Patient Safety Foundation. February 2015. 
23. US Food & Drug Administration. DRUG SHORTAGES AND THE FDA RESPONSE: US 
Food & Drug Administration; 2014. 
24. FDA. Inquiry regarding overseas generic sterile injectable drug manufactering 
25. Woodcock J, Wosinska M. Economic and Technological Drivers of Generic Sterile 
Injectable Drug Shortages. Clinical Pharmacology and Therapeutics. Febuary 2013;93(2). 
26. Barei F, Le Pen C, Simoens S. The Generic Pharmaceutical Industry: moving beyond 
incremental innovation towards re-innovation. Generics and Biosimilars Initiative Journal. 
2013;2(1). 
27. Chabner BA. Drug Shortages A Crititcal Challenge for the Generric-Drug Market. The New 
England Journal ofMedicaine. December 2011;365:2147-2149. 
28. Assistant Secretary For Planning and Evaluation. Economic Analysis of the Causes of Drug 
Shortages: Office of Science and Data Policy; 2011. 
29. The Economist. Going large: A wave of new medicines known as biologics will be good for 
drugmakers, but may not be so good for health budgets. The Economist. January 2015. 
30. Food and Drug Administration. What Are "Biologics" Questions and Answers. FDA.gov. 
August 15, 2015. Available at: 
http://www .fda. gov I AboutFDAICentersOffices/OfficeofMedicalProductsandTobaccolCBE 
RJucm133077.htm. Accessed February 2,2016. 
31. FDA. Information on Biosimilars. FDA.com. February 22, 2016. Available at: 
http://www . fda. gov IDrugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr 
oved! ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/. Accessed 
March 17,2016. 
32. Blackstone EA, Fuhr JP. The Economics of Biosimilars. Am Health Drug Benefits. 
Septembe/October 2013;6(8):469-478. 
33. Food and Drug Administration. Biosimilars. FDA.gov. August 15,2015. Available at: 
WHY SO MANY DRUG SHORTAGES 71 
http://www.fda.gov/Drugs/DevelopmentApprovaIProcess/HowDrugsareDevelopedandAppr 
oved! ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm. 
Accessed February 2,2016. 
34. Hospira. Pfizer Completes Acquisition of Hospira. Hospira.com. September 3,2015. 
Available at: 
http://www.hospira.comlenlabout hospiralnewsroomlpress releases/pfizer acquisition pres 
s release. Accessed February 2,2016. 
35. Ramachandra S. Lessons for the United States: Biosimilar Market Development 
Worldwide. FTC.gov. February 4,2014. Available at: 
https:/ Iwww.ftc.gov/systemlfiles/documents/public events/Follow-
On%20Biologics%20W orkshop%3A %20Impact%20ofOIo20Recent%20Legislative%20and 
%20Regulatory%20Naming%20Proposals%200n%20Competitioniramachandra. pdf. 
Accessed February 2, 2016. 
36. Hirschler B, Shields M. Novartis launches first U.S. 'biosimilar' drug at 15 percent discount. 
Reuters.com. September 3,2015. Available at: http://www.reuters.comlarticle/us-novartis-
drug-idUSKCNOR30C220150903. Accessed February 2,2016. 
37. Fischer E. The Patent cliff:rise of the generics. Pharmaceutical-technology. com. October 5, 
2011. Available at: http://www.pharmaceutical-technology.comlfeatures/featurethe-patent-
cliff-rise-of-the-generics/. Accessed August 21,2015. 
38. Schweitzer SO. How the US Food and Drug Administration Can Solve the Prescription 
Drug Shortage Proble. American Journal of Public Health. May 2013;103(5). 
39. Kotler P, Keller KL. Marketing Management. Vol I. 14E ed. Upper Saddle River: Prentice 
Hall. 
40. Throckmorton ,DC. FDA Response to Drug Shortages: US Food & Drug Administration; 
2014. 
41. Graham JR. A Concentrated Market: Mackinac Center for Public Policy; 2012. 978-0-
9833004-9-6. 
42. Palmer E. Hospira again shipping ketorolac but U.S. faces many drug shortages. 
FiercePharmaManufacturing.com. June 2,2015. Available at: 
http://www.fiercepharmamanufacturing.comlstorylhospira-again-shipping-ketorolac-us-
faces-many-drug-shortages/2015-06-02. Accessed Setember 20, 2015. 
43. Pfizer. Pfizer Completes Acquisition of Hospira. Pfizer.com. September 3,2015. Available 
at: htlp:llwww.pfizer.comlnews/press-release/press-release-
detail/pfizer completes acquisition of hospira. Accessed February 2,2016. 
44. Pierson R, Berkrot B. Pfizer to buy Allergan in $160 billion deal. Reuters.com. November 
24,2015. Available at: http://www.reuters.comlarticle/us-allergan-m-a-pfizer-
idUSKBNOTBOUT20151124. Accessed February 2,2016. 
45. Koons C, Cortez. Bloomberg business. Pfizer and Allergan to Combine With Joint Value of 
$160 Billion. November 22,2015. Available at: 
http://www.bloomberg.comlnews/articles/20 15-11-22/pfizer-allergan-said-to-be-close-to-
150-billion-merger. Accessed February 17, 2016. 
46. Oldfield E. Median Price Chang for Generic Drugs is 0%. Pharmacy Times. October 2014. 
WHY SO MANY DRUG SHORTAGES 72 
47. Silverman E. How Much? Some Generic Drug Prices Are Skyrocketing: Analysis. The wall 
Street Journal. August 2014. 
48. Colliver. Prices soar for some generic drugs. SFGATE. January 2014. 
49. Pollack A. Drug Goes From $13.50 a Tablet to $750, Overnight. The New York Times. 
September 2015. 
50. Pollack A, Creswell J. Martin Shkreli, the Mercurial Man Behind the Drug Price Increase 
That Went Viral. New York Times. September 2015. 
51. Health Policy Briefs. Health Policy Briefs. Health Affairs. September 24,2014. Available 
at: htto:llwww.healthaffairs.org/healthpolicybriefs/brief.php?brief id=124. Accessed 
August 21,2015. 
52. U.S. Food and Drug Administration. Facts About the Current Good Manufacturing 
Practices (CGMPs). u.s. Food and Drug Administration. January 1,2015. 
http://www.fda.gov/Drugs/DevelopmentApprovaIProcess/Manufacturing/ucmI69105.htm. 
Accessed August 24,2015. 
53. Steger J. Pharmaceutical Regulatory Compliance Congress. Pharmaceutical Regulatory 





w&bvm=bv.117604692,d.eWE. Accessed August 25, 2015. 
54. Szalavitz M. Health.Time.com. Time.com. September 17, 2012. Available at: 
http://healthland.time.com/20 12/09/17 Ipharma-behaving-badly-top-l O-drug-company-
settlements/slide/amgen!. Accessed August 28,2015. 
55. Office of Public Affairs. Justice News. The United States Department of Justice. March 10, 
2015. http://www.justice.gov/opa/pr/mcneil-ppc-inc-pleads-guilty-connection-adulterated-
infants-and-childrens-over-counter-liquid. Accessed August 25, 215. 
56. Fox ER. Manufacturing Quality Drives Drug Shortages. Pharmacy Purchasing & Products. 
March 2014. 
http://www.pppmag.com/artic1eI1460IMarch 2014/Manufacturing Quality Drives Drug S 
hortages/. Accessed August 2015. 
57. Meyer. The Anatomy of the Drug Shortages. Anesthesia Patient Safety Foundation. 
2012;27(1 ):7. 
58. Food and Drug Administration. Text Version: Drug Shortages Infographic. u.s. Food and 
Drug Administration Protecting and Promoting Your Health. April 10, 2015. Available at: 
http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm441585.htm. Accessed October 
20,2015. 
59. Fox ER, Birt A, James KB, Kokko H, Salverson S, Soflin DI. ASHP Guidelines on 
Managing Drug Product Shortages in Hospitals and Health Systems. American Journal 
Health-System Pharm. 2009;66: 1399-406. 
60. Sklamberg. FDA Voice- Globalization. FDA.gov. March 18,2015. Available at: 
http://blogs.fda. gOY Ifdavoice/index.php/tag/ globalization!. Accessed October 13, 2015. 
WHY SO MANY DRUG SHORTAGES 73 
61. GAO. Protecting Public Health through Enhanced Oversight of Medical Products. gao.gov. 
February 11, 2015. Available at: 
http://www.gao.govlhighrisk/protecting public health/why did study#t=l . Accessed 
January 30,2016. 
62. Sullivan T. Prescription Drug Shortages: Crisis Abating - Still Need for Pricing Reform. 
Policy and Medicine. December 19,2012. Available at: 
http://www.policymed.coml2012/12/prescription-drug-shortages-crisis-abating-still-need-
for-pricing-reform.html. Accessed September 9,2015. 
63. PDM Healthcare. PDM Healthcare. History of GPO's. 2015. Available at: 
http://www.pdmhealthcare-gpo.comlHistoryOfGPOs.aspx. 
64. Health Care Supply Chain Association. 2025 M Street NW, Suite 800 Washington, DC 200 
36 Phone (202) 367-1162 Fax (202) 367-2162 Web www.SupplyChainAssociation.org 
Email info@SupplyChainAssociation.org A PRIMER ON GROUP PURCHASING 
ORGANIZATIONS Questions and Answers. www.SupplyChainAssociation.org. Available 
at: 
http://c.ymcdn.comlsites/www .supplychainassociation.org/resource/resmgr/research/ gpo pr 
imer.pd£ Accessed September 8,2015. 
65. Jayanthi A. Becker's Review. Becker's Healthcare. july 18,2014. Available at: 
http://www.beckershospitalreview.comlhospital-management -administrationl50-things-to-
know-about-the-country-s-Iargest-gpos.html. Accessed September 9, 2015. 
66. Roger BD, Durrance CPo Group Purchasing Organizations, Monopsony, and Antitrust 
Policy. Managerial and Decison Economics. 2013. 
67. United States Govenment Accountability Office. Group Purchasing Organizations: 
Funding Structure Has Potential Implications for Medicare Cost: United States 
Government; 2014. Report to Congress. 
68. Sethi SP. Group Purchasing Organizations: An Undisclosed Scandal in the U.S. 1st ed. 
New York: Palgrave Macmillan. 
69. Pizzi R. Healthcare GPO revenue to hit $2B in 2010. Healthcare Finance. January 5,2010. 
Available at: http://www.healthcarefinancenews.comlnewslhealthcare-gpo-revenue-hit-2b-
2010. Accessed September 9,2015. 
70. Healthcare Purchasing News. GPO FACTS & FIGURES. CLINICAL INTELLIGENCE 
FOR SUPPLY CHAIN LEADERSHIP. October 2012. Available at: 
http://www.hpnonline.comlresources/GPOs.html. Accessed September 9,2015. 
71. Nelson R. medscape. medscape.com. January 24,2013. Available at: 
http://www.medscape.comlviewartic1e/778146. Accessed March 4,2015. 
72. Blair RD, Piette C. Group Purchasing Organizations, Monopsony, and Antitrust Policy. 
Managerial and Decision Economics. October 2014;35(7):433-443. 
73. Kurian. The AMA Dictionary of Business and Management. New York: Publishing Division 
of the American Management Association; 2013. 
74. Lindsay MA. Antitrust and Group Purchasing. Antitrust. 2009;23(3). 
75. Sethi SP. Group Purchasing Organizations: An Evaluation of Their Effectiveness in 
Providing Services to Hospitals and Thier Patients: International Center for Corporate 
WHY SO MANY DRUG SHORTAGES 
Accountability; 2006. 
76. Kantarjian H. Chemotherapy Drug Shortages in the United States Revisited. Journal of 
Oncology Practice. September 2014;10(5):329-31. 
74 
77. AmosWeb Encyc1onomic. Oligopoly and Monopolistic Competition. amosweb.com. 2015. 
Available at: http://www.amosweb.comlcgi-
binlawb nav.pl?s=wpd&c=dsp&k=0Iigopoly%20and%20monopolistic%20competition. 
Accessed October 13,2015. 
78. Economics Online. Economics Online - Oligopoly. economicsonline.co.uk. 2015. Available 
at: http://www .economicsonline.co. uk/Business economics/Oligopoly.html. Accessed 
October 13, 2015. 
79. Burns LR, Joo-Jin Kim J. The Performance of Group Purchasing Organizations (GPOs) in 
the Health Care Value Chain: A literature Review: Wharton University of Pennsylvania; 
2014. 
80. Weinstein, Weinstein BL. The Role of Group Purchasing Organizations (GPOs) in the U.S. 
Medical Industry Supply Chain. Estudios De Economia Aplicada. 2006;24(3):789-802. 
81. Earl P, Zweig PL. Connecting the Dots: How Anticonpetitive Contracting Practices, 
Kickbacks, and Self-dealing by Hospital Group Purchasing Orgainizations (GPOs) Caused 
the U.S. Drug Shortage. careandcost.com. February 14,2012. Available at: 
http://careandcost.coml2012/02/14/connecting-the-dots-how-anticompetitive-contracting-
practices-kickbacks-and-self-dealing-by-hospital-group-purchasing-organizations-gpos-
caused-the-u-s-drug-shortagel. Accessed October 7, 2015. 
82. Walsh M. When a Buyer for Hospitals Has a Stake in Drugs It Buys. NYTimes. com. March 
26,2002. Available at: http://www.nytimes.com/2002/03/26/business/when-a-buyer-for-
hospitals-has-a-stake-in-drugs-it -buys.html ?pagewanted=all. Accessed October 8, 2015. 
83. Subcommittee on Antitrust, Business Rights, and Competition BUSINESS RIGHTS, AND 
COMPETITION. Hospital Group Purchasing: Lowering Cost at the Expense of Patient 
Health and Medical Innovation? United States Government Printing Office. April 30, 2002. 
Available at: https:l/www.gpo.gov/fdsys/pkg/CHRG-l 07 shrg85 986/htm1/CHRG-
107shrg85986.htm. Accessed August 15,2015. 
84. GAO. Study Suggests Large Buying Groups Do Not Always Offer Hospitals Lower Prices: 
United States Congress; 2002. Testimony. 
85. GAO. Group Purchasing Organizations: Funding Structure Has Potential Implictionsfor 
Medicare Costs: U.S. Congress; 2014. Report to Congress. 
86. Wharten University of Pennsyvania. Knowledge @ Wharton. Hospital Consolidation: Can 
It Work This Time? May 11,2015. Available at: 
http://knowledge.wharton.upenn.edulartic1e/hospital-consolidation-can-it-work-this-timel. 
Accessed November 5, 2015. 
87. Cultler DM, Morton FS. Hospital, Market Share, and Consolidation. Journal of the 
American Medical Association. November 2013;310(18). 
88. Dafny. Hospital Industry Consolidation - Still More to Come? The New England Journal 
of Medic ice. January 2014;370:198-199. 
89. Channick SA. The ACA, Provider Mergers, and Hospital pricing: Experimenting with 
WHY SO MANY DRUG SHORTAGES 75 
Smart, Lower-Cost Health Insurance options. William & Mary Policy Review. 2015;6(2). 
90. Myers C, Lineen. hospital consolidation outlook surviving in a tough economy. Healthcare 
Financial Management. November 2009;63(11). 
91. American Hospital Association. Fast Facts on U.S. Hospitals. 2015. Available at: 
http://www.aha.org/research/rc/stat-studies/fast-facts.shtml. Accessed October 29,2015. 
92. Weltman. THE NATION'S WEALTH ABOVE SENIORS' HEALTH? DRUG 
SHORTAGES RESULTING FROM MEDICARE PART B LEGISLATION. Elder Law 
Journal. July 2015 ;23 :265-296. 
93. Mark M. Challenges Posed by Drug Shortages. American Society ofHealt-System 
Pharmacists. December 9,2002. Available at: 
https:llwww .ashp.org/DocLibrary/PolicylDrugShortages/DShort -abbott -drug.aspx. 
Accessed November 28,2015. 
94. American Hospital Association. AHA Survey on Drug Shortages: American Hospital 
Association; 2011. Survey. 
95. Guharoy R, Noviasky J, Haydar Z, Fakih MG, Hartman C. Coumpounding Pharmacy 
Conundrum: "We Cannot Live Without Them but We Cannot Live With Them". Chest 
Journal. April 2013;143(4). 
96. Lee J. Compounding effort: Quality control, costs drive hospitals to mix drugs. Modern 
Healthcare. March 2013;43(9):12-14. 
97. CONNECTION BETWEEN DRUG SHORTAGES CMSS. Inside Health Reform. 
InsideHealthPolicy.com's. November 14,2012. Available at: 
http://libproxy.umflint.edu:21 06/nursing/docview/1151717879/566DF53B5A lA4C67PQ/2? 
accountid=14584. Accessed Noveber 7,2015. 
98. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 
Drugs. October 6,2015. Available at: 
http://www.fda.gov/Drugs/GuidanceComplianceRegulatorvInformationlPharmacyCompoun 
ding/ucm339764.htm. Accessed November 3,2015. 
99. Food and Drug Administration. The Special Risks of Pharmacy Compounding. For 
Consumers. October 14,2014. Available at: 
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucml07836.htm. Accessed 
November 3, 2015. 
100. American Pharmacists Association. Pharmacist.com. Frequently Asked Questions About 
Pharmaceutical Compounding. November 19,2012. Available at: 
http://www.pharmacist.comlfreguently-asked-questions-about-pharmaceutical-
compounding. Accessed November 5,2015. 
101. Outterson K. Regulating Compounding Pharmacies after NECC. 
Close:block:schoIUnivAuthors Open:block:publicationBlock The New England Journal of 
Medicine. November 2012;367(21):1969-72. 
102. Modem Healthcare. When tragedy hit, providers were quick to respond. Modern 
Healthcare. December 2012;42(52):29. 
103. Meyer T, Martin E, Prielipp R. The Largest Health Care Associated Fungal Outbreak in the 
U.S. The Official Journal of the Anesthesia Patient Safety Foundation (APSF). 
WHY SO MANY DRUG SHORTAGES 
Spring/Summer 2013;28(1):4-7. 
104. Centers for Disease Control and Prevention. Multistate Fungal Meningitis Outbreak 
Investigation. CDC. Gov. March 25,2013. Available at: 
http://www.cdc.gov/hai/outbreaks/infographic.html. Accessed November 28,2015. 
76 
105. Institute for Safe Medication Practices. Sterile Compounding Tragedy Is A Symptom Of A 
Broken System On Many Levels. Ismp.com. October 18,2012. Available at: 
http://www.ismp.org/newsletters/acutecare/showartic1e.aspx?id=34. Accessed November 
28,2015. 
1 06. Young. Outsourced Compounding Can Be Problematic. American Society of Health-System 
Pharmacists. December 1, 2002. Available at: 
http://www .ashp.org/menuIN ews/PharmacyN ewslNewsArtic1e.aspx?id= 1125 . Accessed 
November 28,2015. 
107. Tyler S. [q~J:Understanding Drug & Managing Shortages. American Society of Health-System 
Pharmacits. December 9,2002. Available at: 
https:/ /www.ashp.org/DocLibraryiPolicylDrugShortages/DShort-abbott-drug.aspx. 
Accessed November 28,2015. 
108. Kaakeh R, Sweet BV, Reilly C, Bush C, DeLoach S. Impact of drug shortages on U.S. 
health systems. American Journal of Health-System Pharmacy. October 2011 ;68( 19): 1811-
1819. 
109. Navigating Drug Shortages in American Healthcare: A Premier healthcare alliance analysis. 
Premierinc.com. March 2011. Available at: https:lllegacy.premierinc.com/about/newsI11-
mar/drug-shortage-white-paper-3-28-11.pdf. Accessed January 10, 2015. 
110. Institute for Safe Medication Practices. Drug shortages: National survey reveals high level 
of frustration, low level of safety. ISMO.org. September 23,2010. Available at: 
http://www.ismp.org/newsletters/acutecareiartic1es/20 1 00923.asp . Accessed December 1, 
2015. 
111. American Society of Anesthesiologist. Drug shortages. American Society of 
Anesthesiologist. March 2012. Available at: https://www.asahq.org/advocacy/federal-
activities/regulatory-activityldrug-shortages#Drug%20Shortages%20Survey. Accessed 
December 3,2015. 
112. O'Donnell JT, Vogenberg RF. Drug Shortages Pose Problems for P&T Committees in 
Accountable Care Organizations. Pharmacy and Therapeutics. July 2013;38(7):404-406. 
113. Mazer-Amirshahi M, Pourmand A, Singer S, Pines JM. Critical Drug Shortages: 
Implications for Emergency Medicine. Academic Emergency Medicine. June 
2014;21(6):704-711. 
114. Jagsi R, Spence R, Rathmel KW. Ethical Considerations for the Clinical Oncologist in an 
Era of Oncology Drug Shortages. Oncologist. February 2014;9(2):186-192. 
115. Johnson LM, Levine D. Allocation of Drugs in Short Supply. AMA Journal of Ethics. 
August 13, 2013. Available at: http://journalofethics.ama-assn.org/2013/08/ecas2-
1308.htm!. Accessed January 3,2015. 
116. Committee on Oversight and Government Reform. DRUG SHORTAGE CRISIS: LIVES 
ARE IN THE BALANCE: House of Representative, US Government; 2011. Serial No. 112-
WHY SO MANY DRUG SHORTAGES 
102. 
117. Fink S. Drug Shortages Forcing Hard Decisions on Rationing Treatments. nytimes.com. 
January 29,2016. Available at: http://www.nytimes.coml2016/01l29/us/drug-shortages-
forcing-hard-decisions-on-rationing-treatments.html? FO. Accessed March 18,2016. 
77 
118. Hoffmaster B, Hooker C. Tragic Choices and Moral Compromise: The Ethics of Allocating 
Kidneys for Transplantation. Milbank Quarterly. September 2013;91(3):528-557. 
119. U.S. Food and Drug Administration. History. About FDA. March 23,2015. Available at: 
http://www.fda.gov/AboutFDAlWhatWeDolHistory!. Accessed January 4,2016. 
120. U.S. Food and Drug Administration. FDA Organization Overview. About FDA. November 
2, 2015 . Available at: 
http://www.fda.gov/AboutFDAICentersOffices/OrganizationCharts/ucm393155.htm. 
Accessed January 4,2016. 
121. U.S. Food and Drug Administration. Members of the Drug Shortages Task Force. FDA-
Drugs. December 10,2014. Available at: 
http://www.fda.gov/Drugs/DrugSafetyiDrugShortages/ucm358208.htm. Accessed January 
4,2015. 
122. Kweder SL. Prescription Drug Shortages: Examining a Public Health Concern and 
Potential Solutions. Washington, D.C: U.S. Government; 2011. Testomony. 
123. GAO. DRUG SHORTAGES Public Health Threat Continues, Despite Efforts to Help 
Ensure Product Availability. Washington, DC: United States Government Accountability 
Office; 2014. Report to Congressional Addressees. 
124. University of Utah Health Care. National drug shortages at all-time high, threatening patient 
care. University o/Utah Health Care. 2015. Available at: 
http://healthcare.utah.edu/publicaffairs/news/currentI02-27-
2014 National drug shortages.php. Accessed January 4,2016. 
125. Committee on Oversight and Government Reform. FDA's Contribution to the Drug 
Shortage Crisis. Washington D.C.: Committee on Oversight and Government Reform; 
2012. Staff Report. 
126. Roy A. How Margaret Hamburg's FDA Causes Cancer Drug Shortages. Forbes.com. June 
15,2012. Available at: http://www.forbes.comlsites/theapothecary!2012/06/15/how-
margaret-hamburgs-fda-causes-cancer-drug-shortages/#2715e4857 aOb3e30b870 14ca. 
Accessed January 10,2015. 
127. House Committe and Oversight and Government Reform. Oversight Report: Meaningless 
Red Tape Causing Medication Shortages. oversight.house.gov. June 15,2012. Available at: 
https:lloversight.house.gov/release/oversight-report-meaningless-red-tape-causing-
medication-shortages/. Accessed January 17,2015. 
128. FDA. Enforcement Activity. Inspections, Compliance, Enforcement, and Criminal 
Investigations. May 18,2015. Available at: 
http://www.fda.gov/ICECIlEnforcementActions/ucm247813.htm. Accessed January 7, 
2016. 
129. FDA. Teva Parenterals Medicines, Inc .. Inspections, Compliance, Enforcement, and 
Criminal Investigations. December 11, 2009 . Available at: 
WHY SO MANY DRUG SHORTAGES 78 
http://www.fda.gov/ICECIIEnforcementActions/WarningLetters/ucm209222.htm. Accessed 
January 10,2016. 
130. Rye B. Medicare Price Controls Worsen Drug Shortages, Boost Gray Market: Bloomberg 
Government Study; 2012. 
131. Gaffuey A. FDA Fires Back at Legislative Critics, Blames Manufacturers for Drug 
Shortages. Regulatory Affairs Professionals Society. July 25, 2012. Available at: 
http://www.raps.orglfocus-online/news/news-artic1e-view/artic1e11967/. Accessed January 
7,2016. 
132. Weiss D. FDA Rejects Blame for Drug Shortages. Pharmacy times. com. Augus 7,2012. 
Available at: http://www.pharmacytimes.comlnews/fda-rejects-blame-for-drug-shortages. 
Accessed January 7,2016. 
133. Gaffuey A. Regulatory Affairs Professionals Society. FDA Fires Back at Legislative 
Critics, Blames Manufacturers for Drug Shortages - See more at: 
http://www. raps. orglfocus-onlinelnewslnews-article-
viewlarticleI1967/#sthash.6fxdSdqE.dpuf. July 25,2012. Available at: 
http://www.raps.org/focus-online/news/news-artic1e-view/artic1e11967/. Accessed February 
22,2016. 
134. Food and Drug Administration. Strategic Plan for Preventing and Mitigating Drug 
Shortages: U.S. Government; 2013. 
135. FDA. Prescription Drug Shortages: Examining a Public Health Concern and Potential 
Solutions. FDA.gov. December 15,2011. Available at: 
http://www.fda.govlNewsEvents/Testimony/ucm282956.htm. Accessed January 10,2015. 
136. The U.S. Federal Trade Commission and the Antitrust Division. COMPETITION ISSUES 
IN THE DISTRIBUTION OF PHARMACEUTICALS: The U.S. Federal Trade Commission; 
2014. 
137. Dey S. If I follow US standards, I will have to shut almost all drug facilities: G N Singh. 
Business-Standard.ocm. January 30,2014. Available at: http://www.business-
standard.comlartic1e/economy-policylif-i-follow-us-standards-i-will-have-to-shut-almost-
all-drug-facilities-g-n-singh-114013000034 l.html. 
138. Clarke T. FDA chief says U.S. not targeting Indian drug companies in crackdown. 
rueters.com. February 21, 2014. Available at: http://www.reuters.comlartic1e/fda-india-
drug-safety-idl!SL2NOL025P20140221. Accessed January 18,2015. 
139. The White House. Executive Order 13588 -- Reducing Prescription Drug Shortages. 
Whitehouse.gove. October 31,2011. Available at: https:llwww.whitehouse.gov/the-press-
office/20 1111 0/31/executive-order-13588-reducing-prescription-drug-shortages. Accessed 
January 10, 2015. 
140. Emanuel EJ. Shortchanging Cancer Patients. The New York Times. August 2011. 
141. Krasomil A. Measuring the impact of the Medicare Prescripton Drug, Improvement, and 
Modernization Act of 2003 on Shortages of Sterile Injectable Oncology Drugs. 
Dukespace.lib.duke.edu. April 20, 20 12;:Prepared for: The Office of Senator Robert P. 
Casey, Jr. Available at: 
http://dukespace.lib.duke.eduldspaceibitstreamlhandle/l 016115236/evan krasomil MP .pdf? 
sequence=3 . Accessed January 14,2015. 
WHY SO MANY DRUG SHORTAGES 
142. Gatesman ML, Smith, TJ. The Shortage of Essential Chemotherapy Drugs in the United 
States. N Engl J Med. November 2011;365:1653-1655. 
143. Twombly. Medicare Cost Containment Strategy Targets Several Oncology Drugs. JNCI J 
Natl Cancer Inst. August 2004;96(17): 1268-1270. 
79 
144. United States General Accounting Office. Payments for Covered Outpatient Drugs Exceed 
Providers' Cost. Washington, DC: United States Government; 2001. Report to 
Congressional Committees. 
145. Graham JR. The Shortage of Generic Sterile Injectable Drugs: Diagnosis and Solutions. 
Mackinac Center for Public Policy. June 14,2012. Available at: 
https:llwww.mackinac.org/17073. Accessed January 14,2015. 
146. Federgruen A. The Drug Shortage Debacle- And How to Fix It. WSJ.com. March 1,2012. 
Available at: 
http://www.wsj.comlartic1es/SB10001424052970203986604577253242913478400. 
Accessed January 15,2015. 
147. Cobb P. Testimony on: Drug Shortages: Why They Happen and What They Mean. 
Washington, DC: United States Senate Committee on Finance; 2011. 
148. McCartney M. Daily drug shortages place avoidable pressure on primary care. BMJ. May 
2015;350:2514. 
149. Torjesen I. Drug shortages: it's time for Europe to act. The Pharmaceutical Journal. 
January 2015;294(7847). 
150. Pauwels K, Simoens S, Casteels M, Huys I. Insights into European Drug Shortages: A 
Survey of Hospital Pharmacists. PLoS One. March 2015;10(3). 
151. McLaughlin M, Kotis D, Thomson K, et al. Effects on Patient Care Caused by Drug 
Shortages: A Survey. J Manag Care Pharm. November/December 2013;19(9):783-88. 
152. Schoen D. The Drug Shortage Crisis in America. Forbes. February 2012. 
153. Koba M. Drug Shortage in the U.S. May Pose Deadly Problem for Patients. Time. January 
2015. 
154. Silverman E. The Number of Drug Shortages - And Patient Frustration - Keeps Growing. 
WSJ.com. June 1,2015. Available at: http://blogs.wsLcomlpharmalot/2015/06/01lthe-
number-of-drug-shortages-and-patient-frustration-keeps-growing!. Accessed March 18, 
2016. 
155. The Health Strategies Consultancy LLC. Follow the Pill: Understanding the u.s. 
Commercial Pharmaceutical Supply Chain: Prepared for The Kaiser Family Foundation; 
2005. 
156. Cherici C, McGinnis P, Russell, W. Buyer beware: Drug shortages and the gray market. 
Premier. August 2011. Available at: https:lllegacy.premierinc.com/about/news/11-
aug/Gray-Market/Gray-Market-Analysis-08152011.pd£ Accessed January 22,2015. 
157. Merriam-Webster dictionary. Gray market. Merriam- Webster. nd. Available at: 
http://www.merriam-webster.comldictionary/gray%20market. Accessed October 10,2015. 
158. House Committee on Oversight and Government Reform. Shining Light on the "Gray 
Market". Washington D.C.: The United States congress; 2012. Staff Report. 
159. Food and Drug Administration. CPG Sec. 160.900 Prescription Drug Marketing Act--
WHY SO MANY DRUG SHORTAGES 80 
Pedigree Requirements under 21 CFR Part 203. Inspections, Compliance, Enforcement, and 
Criminal Investigations. March 20,2015. Available at: 
http://www.fda.gov/ICECIIComplianceManuals/CompliancePolicyGuidanceManuallucm07 
3857.htm. Accessed January 26,2016. 
160. Majority Committee Staff. The Committee on Energy and Commerce. docs.house.gov. 
February 25,2014. Available at: 
http://docs.house.gov/meetings/IF/IF02/20140227/101804/HHRG-113-IF02-20140227-
SD002.pdf. Accessed January 25, 2015. 
161. Food and Drug Adminstration. Counterfeit Drug Task Force Report October 2003 -
Backround: Vunerabilities in the U.S. Drug Distribution System. Drug Safety and 
Availability. October 2003. Available at: 
http://www.fda.gov/Drugs/DrugSafety/ucm174479.htm. Accessed January 24,2015. 
162. Blackstone EA, Fuhr JP, Pociask S. The Health and Economic Effects of Counterfeit Drugs. 
Am Health Drug Benefits. June 2014;7(4):216-224. 
163. Food and Drug Administration. FDA Initiative to Combat Counterfeit Drugs. Drug Safety 
and Availability. September 10,2009. Available at: 
http://www.fda.gov/Drugs/DrugSafety/ucm180899.htm. Accessed January 25,2015. 
164. Valdez ML. Challenges and Opportunities of Globalization. FDA.gov. September 18,2014. 
Available at: http://www.fda.govlNewsEvents/Speeches/ucm415612.htm. Accessed 
February 28,2016. 
165. National Community Pharmacists AssociationNational Community Pharmacists 
Association. "Review of the Proposed Generic Drug and Biosimilars User Fees and 
Further Examination of Drug Shortages": United States House of Representatives 
Committee on Energy and Commerce; 2012. Hearing. 
166. Fox E. Current Trends In Drug Shortages: National Pharmacy Forum; 2013. Presentation. 
167. Deloitte. 2015 Global life sciences outlook Adapting in an era of transformation 2014. 
Deloitt.market analysis of generics. 
168. Rattinger GB, Jain R, Ju J, Mullins DC. Principles of Economics Crucial to Pharmacy 
Students' Understanding of the Prescription Drug Market. American Journal of 
Pharmaceutical Education. June 2008;72(3):61. 
169. Zwolinski M. The Ethic of Price Gouging. St. John University.edu. November 10,2014. 
Available at: http://website-box.net/site/facpub.stjohns.edu. Accessed January 15, 2016. 
170. GAO. Drug Saftey FDA Has Conducted More Foreign Inspections and Begun to Improve 
Its Information on Foreign Establishments, but More Progress Is Needed. GOA.gov. 
September 2010. Available at: http://www.gao.gov/products/GAO-10-961. Accessed 
February 28,2016. 
171. Feldstein PJ. Health Care Economics. Voll. 7th ed. Clifton Park: Delmar; 2012. 
172. Polite BN, Ward JC, Cox JV, Morton RF, Hennessy J, Page RD. Payment for Oncolytics in 
the United States: A History of Buy and Bill and Proposals for Reform. Journal of 
Oncology Practice. November 2014;10(6):357-362. 
173. Goodbaum B. The Race is On: Chain of Custody in the Pharmaceutical Supply Chain. 
inboundlogistics.com. April 2015. Available at: 
WHY SO MANY DRUG SHORTAGES 
http://www.inboundlogistics.comlcms/artic1e/the-race-is-on-chain-of-custody-in-the-
pharmaceutical-supply-chain!. Accessed January 31,2016. 
81 
174. HEARING BEFORE THE SUBCOMMITTEE ON OVERSIGHT AND 
INVESTIGATIONS OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE 
OF REPRESENTATIVES. THE HEPARIN DISASTER: CHINESE COUNTERFEITS AND 
AMERICAN FAILURES. Washington D.C.: United States Government; 2008. Hearing. 
175. Trieste Mv. Ensuring a Robust Raw-Materials Supply Chain. BioPharm International. july 
2014;27(7). 
176. Challener CA. Supply Chain Security Tops Concerns for Biopharma Raw Materials. 
Pharmaceutical Technology Sourcing and Management. September 2014; 1 0(9). 
177. Federal Trade Commission. Examining Health care Competition. Paper presented at: 
Hosted by the Federal Trade Commission and U.S. Department of Justice, Antitrust 
Division, 2015; Washington DC. 
178. American Society of Health-System Pharmacist. Best Practices for Hospital and Health-
System Pharmacy 2013-2014: American Society of Health-System Pharmacist; 2013. 
179. Stiff, Johnson, Tour K. Scarcity and Hoarding: Economic and Social Explanations and 
Marketing Implications. Association for Consumer Research. 1971. Available at: 
http://www.acrwebsite.org/volumes/5764/volumes/v02INA-02. Accessed November 28, 
2015. 
180. Fleming H. Stop stockpiling! Drug Topics. February 1999;143(4):65. 
181. Association of State and Territorial Health Officials. Coping with and Mitigating the Effects 
of Shortages of Emergency Medications. EMS.gov. December 2012. Available at: 
http://www.ems.gov/pdf/2013/ASTHO Shortages of Emergency Meds.pd£ Accessed 
November 30, 2015. 
182. National Conference of State Legislatures. OVERSIGHT OF THE U.S. DRUG SUPPLY. 
National Conference of State Legislatures. October 1,2014. Available at: 
http://www.ncsl.org/research!healthlregulation-and-oversight-of-the-u-s-drug-supply-h-r-
3204-the-drug-quality-and-security-act.aspx. Accessed November 30,2015. 
183. Duham DF, Sheffet J. Gray Markets and the Legal Status ofParellel Importation. Journal of 
Marketing. July 1988;52(3):75. 
184. Allen TJ. Grey Market Drugs: Profiting from Poorly Managed U.S. Health Care. 
Corpwatch.org. January 22,2012. Available at: 
http://www.corpwatch.org/artic1e.php?id=15666. Accessed January 28,2016. 
185. Woodward C. Prices gone wild: Grey market 'scalpers' scoring windfall in American drug 
market. CMAJ. February 2012;184(2):119-120. 
186. Feldstein PJ. Health and Economic Policy Perspective Issues. Voll. 5th ed. Chicago: 
Aupha; 2011. 
187. Cohen LP. Many Medicines Are Potent Years Past Expiration Dates. Wall Street Journal. 
March 2000. 

